Citation Report

List of articles citing

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

DOI: 10.1038/nature03445
Nature, 2005, 434, 917-21.

#	Paper	IF	Citations
2252	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. **2011**, 121, 2750		11
2251	Rapid activation by interferon alpha of a latent DNA-binding protein present in the cytoplasm of untreated cells. **1989**, 86, 1203-7		199
2250	Pancreatic cancer. **2004**, 363, 1049-57		1569
2249	Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. **2005**, 70, 139-48		145
2248	Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. **2005**, 65, 7612-21		141
2247	Dissecting cancer pathways and vulnerabilities with RNAi. **2005**, 70, 435-44		27
2246	Polygenic inherited predisposition to breast cancer. **2005**, 70, 35-41		25
2245	An Achilles' heel for breast cancer?. **2005**, 12, 387-8		4
2244	Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. **2005**, 7, 493-500		122
2243	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. **2005**, 4, 421-40		691
2242	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature*, **2005**, 434, 913-7	50.4	3484
2241	Medicine: aborting the birth of cancer. *Nature*, **2005**, 434, 829-30	50.4	36
2240	Climate change: water cycle shifts gear. *Nature*, **2005**, 434, 830-3	50.4	65
2239	Poly(ADP-ribose). The most elaborate metabolite of NAD+. **2005**, 272, 4576-89		242
2238	Oh what a tangled web it weaves: BRCA1 and DNA decatenation. **2005**, 8, 95-7		8
2237	BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. **2005**, 8, 255-65		312
2236	A positive defect. **2005**, 5, 333-333		

2235	Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. **2005**, 4, 1176-8	143
2234	Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. **2005**, 19, 1951-67	612
2233	Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. **2005**, 65, 11597-604	269
2232	Treating cancer by targeting a weakness. **2005**, 353, 949-50	36
2231	B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. **2005**, 280, 33756-65	110
2230	Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. **2005**, 23, 7772-4	13
2229	Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. **2005**, 65, 10145-8	160
2228	The Fanconi Anemia/BRCA pathway: new faces in the crowd. **2005**, 19, 2925-40	303
2227	Cooperation of the Cockayne syndrome group B protein and poly(ADP-ribose) polymerase 1 in the response to oxidative stress. **2005**, 25, 7625-36	94
2226	The molecular basis of prostate cancer. **2005**, 66, 612-6	3
2225	Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. **2005**, 4, 703-6	51
2224	Targeted Therapy for BRCA2 Deficient Tumors. **2005**, 4, 707-8	1
2223	BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. **2005**, 4, 934-6	123
2222	Applications of genomics in NSCLC. **2005**, 50, S33-S40	34
2221	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. **2005**, 48, 5100-3	67
2220	Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. **2005**, 11, 456-63	83
2219	DNA repair inhibition: a selective tumour targeting strategy. **2005**, 11, 503-11	84
2218	Targeting the DNA repair defect of BRCA tumours. **2005**, 5, 388-93	126

2217	Breast Cancer. **2006**,	2
2216	BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. **2006**, 5, 1396-404	52
2215	PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. **2006**, 34, 6170-82	579
2214	The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer. **2006**, 23, 131-136	5
2213	Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. **2006**, 34, 1685-91	165
2212	Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. **2006**, 19, 1580-94	309
2211	Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. **2006**, 66, 8109-15	969
2210	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. **2006**, 34, 1416-26	391
2209	Necrotic death as a cell fate. **2006**, 20, 1-15	639
2208	Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. **2006**, 350, 352-7	59
2207	Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. **2006**, 350, 1056-62	66
2206	Traffic safety for the cell: influence of cyclin-dependent kinase activity on genomic stability. **2006**, 371, 1-6	11
2205	Inhibition of poly(ADP-ribose) polymerase in cancer. **2006**, 6, 364-8	91
2204	Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. **2006**, 356, 257-65	82
2203	Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. **2006**, 22, 719-729	588
2202	Deconstructing the molecular portrait of basal-like breast cancer. **2006**, 12, 537-44	119
2201	Emerging cancer therapeutic opportunities target DNA-repair systems. **2006**, 27, 338-44	99
2200	Familial Breast Cancer [What are the Choices, What Are the Questions?. **2006**, 1, 6-7	1

2199	The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. **2006**, 2, 179-85	50
2198	PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. **2006**, 3, 117-23	49
2197	Molecular pathogenesis of Fanconi anemia: recent progress. **2006**, 107, 4223-33	295
2196	Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. **2006**, 18, 135-43	30
2195	Surgical management of recurrent localized eyelid amyloidosis. **2006**, 22, 308-9	12
2194	Proteomics success story. Novel biomarkers for DNA damage response pathways: insights and applications for cancer therapy. **2006**, 6 Suppl 2, 69-71	2
2193	Human papillomavirus 6a lesions of the lower eyelid and genitalia. **2006**, 22, 311-3	3
2192	Lacrimal gland amyloidosis. **2006**, 22, 306-8	15
2191	Conjunctival squamous cell carcinoma of the orbit 40 years after enucleation. **2006**, 22, 299-301	15
2190	Brown tumor of secondary hyperparathyroidism involving the superior orbit and frontal calvarium. **2006**, 22, 304-6	14
2189	Congenitally enlarged extraocular muscles: can congenital thyroid eye disease exist in a euthyroid infant?. **2006**, 22, 314-6	7
2188	Delayed presentation of orbito-cerebral abscess caused by pencil-tip injury. **2006**, 22, 316-7	14
2187	Bilateral lacrimal system involvement by sclerosing extramedullary hematopoietic tumor. **2006**, 22, 296-8	11
2186	Orbital metastasis from ovarian carcinoma in a patient with BRCA-2 mutation. **2006**, 22, 298-9	0
2185	Bilateral lower eyelid margin erosion associated with lichen planus. **2006**, 22, 310-1	1
2184	Orbital lymphoma simulating thyroid orbitopathy. **2006**, 22, 302-4	16
2183	Osteosarcoma after external beam radiation therapy for recurrent choroidal melanoma. **2006**, 22, 301-2	1
2182	Basal cell carcinoma of the caruncle. **2006**, 22, 313-4	4

2181	Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma. **2006**, 1, 599-605		
2180	Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation. **2006**, 1, 12		11
2179	New targets and challenges in the molecular therapeutics of cancer. **2006**, 62, 5-14		27
2178	New approaches to molecular cancer therapeutics. **2006**, 2, 689-700		307
2177	Topoisomerase I inhibitors: camptothecins and beyond. **2006**, 6, 789-802		1510
2176	Strategies for optimizing combinations of molecularly targeted anticancer agents. **2006**, 5, 649-59		288
2175	The role of double-strand break repair - insights from human genetics. **2006**, 7, 45-54		449
2174	Poly(ADP-ribose): novel functions for an old molecule. **2006**, 7, 517-28		1523
2173	The telomeric PARP, tankyrases, as targets for cancer therapy. **2006**, 94, 341-5		64
2172	Validating cancer drug targets. *Nature*, **2006**, 441, 451-6	50.4	131
2171	Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. **2006**, 25, 1305-14		201
2170	Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. **2006**, 25, 5885-97		180
2169	The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. **2006**, 25, 5864-74		448
2168	Fanconi anaemia genes and susceptibility to cancer. **2006**, 25, 5875-84		157
2167	Clinical management of BRCA1 and BRCA2 mutation carriers. **2006**, 25, 5825-31		69
2166	Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. **2006**, 16, 1040-4		70
2165	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. **2006**, 16, 938-42		39
2164	BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. **2006**, 5, 135-42		114

2163	New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. **2006**, 37, 203-18	56
2162	Update on hereditary breast cancer. **2006**, 8, 14-21	7
2161	The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. **2006**, 18, 145-51	105
2160	BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?. **2006**, 1766, 205-16	18
2159	Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. **2006**, 33, 513-20	22
2158	Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. **2006**, 16, 51-8	87
2157	Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. **2006**, 600, 79-88	36
2156	Disruption of the Fanconi anemia pathway in human cancer in the general population. **2006**, 5, 1637-9	5
2155	Applications of fluorescence for detecting rare sequence rearrangements in vivo. **2006**, 5, 2715-9	12
2154	Elegance, silence and nonsense in the mutations literature for solid tumors. **2006**, 5, 349-59	20
2153	Clinical management of BRCA1 and BRCA2 mutation carriers. **2006**, 3, 2-3	7
2152	Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53. **2006**, 34, 1036-49	23
2151	Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links. **2006**, 34, 2751-60	73
2150	Functional interrogation of breast cancer: from models to drugs. **2006**, 1, 569-84	3
2149	A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1. **2006**, 5, 2364-70	18
2148	Prophylaktische Chirurgie bei Brust- und Eierstockkrebsrisiko. Ein Überblick über die internationale Forschungsliteratur zu Einstellungen, Inanspruchnahmeverhalten und Lebensqualität. **2006**, 66, 1035-1049	1
2147	Targeting the double-strand DNA break repair pathway as a therapeutic strategy. **2006**, 12, 4463-8	85
2146	BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. **2006**, 6, 187-96	8

2145	Declaration of patent applications as financial interests: a survey of practice among authors of papers on molecular biology in Nature. **2006**, 32, 658-61	5
2144	Targeting DNA repair proteins: a promising avenue for cancer gene therapy. **2006**, 6, 111-23	27
2143	Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. **2006**, 66, 5744-56	108
2142	Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. **2006**, 12, 7033-8	32
2141	Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. **2006**, 119, 3284-95	54
2140	Pharmacogenomics and gemcitabine. **2006**, 17 Suppl 5, v13-16	20
2139	Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. **2006**, 26, 9377-86	159
2138	Chemotherapeutic approaches for targeting cell death pathways. **2006**, 11, 342-57	348
2137	Targeting the ubiquitin-proteasome pathway in breast cancer therapy. **2006**, 2, 121-35	20
2136	Demystifying basal-like breast carcinomas. **2007**, 60, 1328-32	41
2135	DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. **2006**, 24, 3799-808	229
2134	In Reply. **2006**, 24, 2970-2971	1
2133	Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. **2006**, 66, 8219-26	104
2132	Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. **2006**, 66, 9722-30	49
2131	Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. **2006**, 176, 309-18	73
2130	Communicating BRCA1 and BRCA2 genetic test results. **2006**, 24, 2969-70; author reply 2970-1	11
2129	BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. **2007**, 13, 7225-7	8
2128	Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. **2007**, 282, 16441-53	202

2127	Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. **2007**, 28, 2082-8	72
2126	ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. **2007**, 13, 2728-37	631
2125	Role of autophagy in breast cancer. **2007**, 3, 610-3	120
2124	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. **2007**, 4, 578-90	107
2123	Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. **2007**, 13, 519-35	23
2122	Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. **2007**, 13, 6252-6	45
2121	The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. **2007**, 6, 2290-302	78
2120	Non-homologous DNA end joining in anticancer therapy. **2007**, 7, 243-50	6
2119	What makes tumors multidrug resistant?. **2007**, 6, 2782-7	89
2118	DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. **2007**, 6, 2344-7	115
2117	BRCA2 function and the central nervous system. **2007**, 6, 2453-7	10
2116	Germline genetic variation and breast cancer survival: prognostic and therapeutic implications. **2007**, 3, 491-5	3
2115	Gene-expression analysis and the basal-like breast cancer subtype. **2007**, 3, 55-63	29
2114	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. **2007**, 104, 19482-7	189
2113	Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. **2007**, 13, 1383-8	250
2112	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. **2007**, 104, 12111-6	343
2111	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. **2007**, 104, 12117-22	241
2110	BRCA1, a potential predictive biomarker in the treatment of breast cancer. **2007**, 12, 142-50	125

2109	Poly(ADP-ribosyl)ation in mammalian ageing. **2007**, 35, 7456-65	85
2108	High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. **2007**, 67, 2169-77	15
2107	Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. **2007**, 13, 4-10	37
2106	Hereditary Breast Cancer. **2007**,	
2105	RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. **2007**, 67, 9658-65	128
2104	DNA replication-associated lesions: importance in early tumorigenesis and cancer therapy. **2007**, 35, 1352-4	3
2103	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. **2007**, 2, 165-173	
2102	Cockayne syndrome exhibits dysregulation of p21 and other gene products that may be independent of transcription-coupled repair. **2007**, 145, 1300-8	16
2101	Targeting DNA repair as a promising approach in cancer therapy. **2007**, 43, 1791-801	80
2100	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. **2007**, 43, 2124-33	108
2099	Haploinsufficiency of poly(ADP-ribose) polymerase-1-mediated poly(ADP-ribosyl)ation for centrosome duplication. **2007**, 359, 426-30	16
2098	Our cells get stressed too! Implications for human disease. **2007**, 39, 148-50	7
2097	Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. **2007**, 33, 565-77	140
2096	ATR signaling mediates an S-phase checkpoint after inhibition of poly(ADP-ribose) polymerase activity. **2007**, 6, 742-50	22
2095	Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. **2007**, 248, 1-17	79
2094	Targeting base excision repair to improve cancer therapies. **2007**, 28, 345-74	40
2093	Right on target: eradicating leukemic stem cells. **2007**, 13, 470-81	104
2092	Chromogenic and fluorescent in situ hybridization in breast cancer. **2007**, 38, 1105-22	77

2091 Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. **2007**, 83, 220-30 53

2090 Triple-negative breast cancer: therapeutic options. **2007**, 8, 235-44 664

2089 182 INVITED Molecular biology of anaplastic large-cell lymphoma. **2007**, 5, 48-49

2088 183 INVITED Molecular diagnosis and prognosis in rhabdomyosarcoma. **2007**, 5, 49

2087 184 INVITED The pros and cons of signal transduction inhibitors in breast cancer. **2007**, 5, 49

2086 185 INVITED Inhibiting angiogenesis□new weapon in the therapeutic armamentarium. **2007**, 5, 49

2085 186 INVITED Synthetic lethal approaches as potential therapies for tumours deficient in DNA repair pathways. **2007**, 5, 49

2084 187 INVITED Challenges and opportunities in the intergration of new and old treatments. **2007**, 5, 49

2083 188 INVITED Lessons and questions from the overview. **2007**, 5, 49-50

2082 Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality. **2007**, 14, 924-31 27

2081 Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery. **2007**, 1

2080 Breast Cancer Chemosensitivity. **2007**, 2

2079 Novel agents in ovarian cancer. **2007**, 16, 1227-39 9

2078 Treating the genetic make-up of breast cancer: a new fashion?. **2007**, 7, 1065-7 2

2077 Therapeutic potential of drugs to modulate DNA repair in cancer. **2007**, 11, 783-99 25

2076 p53, BRCA1 and breast Cancer chemoresistance. **2007**, 608, 70-86 31

2075 BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. **2007**, 30, 316-8 10

2074 Management of women at increased risk for hereditary breast cancer. **2006**, 27, 51-67 13

2073	Ligand bridging of the DNA Holliday junction: molecular recognition of a stacked-X four-way junction by a small molecule. **2007**, 46, 3850-4	34
2072	A colorimetric substrate for poly(ADP-ribose) polymerase-1, VPARP, and tankyrase-1. **2007**, 46, 2066-9	18
2071	Ligand Bridging of the DNA Holliday Junction: Molecular Recognition of a Stacked-X Four-Way Junction by a Small Molecule. **2007**, 119, 3924-3928	13
2070	A Colorimetric Substrate for Poly(ADP-Ribose) Polymerase-1, VPARP, and Tankyrase-1. **2007**, 119, 2112-2115	
2069	XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. **2007**, 48, 491-500	32
2068	Processing of nonconventional DNA strand break ends. **2007**, 48, 772-82	28
2067	Novel poly(ADP-ribose) polymerase-1 inhibitors. **2007**, 17, 542-5	15
2066	Poly(ADP-ribose) makes a date with death. **2007**, 11, 644-53	129
2065	Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. **2007**, 8, 29	117
2064	A mouse model of basal-like breast carcinoma with metaplastic elements. **2007**, 211, 389-98	118
2063	Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. **2007**, 26, 2048-57	132
2062	BRCA1 dysfunction in sporadic basal-like breast cancer. **2007**, 26, 2126-32	466
2061	Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. **2007**, 26, 3857-67	66
2060	Targeted cancer therapies based on the inhibition of DNA strand break repair. **2007**, 26, 7816-24	120
2059	DNA damage signalling guards against activated oncogenes and tumour progression. **2007**, 26, 7773-9	438
2058	Genome instability and oncogenesis. **2007**, 41, 329-339	6
2057	Utilizing RNA interference to enhance cancer drug discovery. **2007**, 6, 556-68	211
2056	HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. **2007**, 14, 1143-51	21

2055	Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury. **2007**, 151, 998-1005	33
2054	Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. **2007**, 20, 1298-306	44
2053	Why we will need to learn new skills to control cancer. **2007**, 37, 201-4	2
2052	PolyADP-ribosylation and cancer. **2007**, 98, 1528-35	120
2051	DNA double-strand break repair: from mechanistic understanding to cancer treatment. **2007**, 6, 923-35	478
2050	Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. **2007**, 6, 1018-31	73
2049	Radioresistant glioma stem cells--therapeutic obstacle or promising target?. **2007**, 6, 1391-4	32
2048	TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. **2007**, 6, 1485-95	66
2047	Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase. **2007**, 313, 984-96	51
2046	Electron microscopy reconstructions of DNA repair complexes. **2007**, 17, 215-20	8
2045	Treatment of hereditary breast cancer. **2007**, 34, 384-91	12
2044	Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. **2007**, 27, 311-323	219
2043	Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. **2007**, 64, 3219-32	20
2042	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. **2007**, 52, 963-977	10
2041	Erblicher Brust- und Eierstockkrebs. **2007**, 19, 202-209	2
2040	Genomic instability: on the birth and death of cancer. **2007**, 9, 216-20	13
2039	Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. **2008**, 7, 83-9	27
2038	[Ovarian carcinoma. Do the subtypes reflect different diseases?]. **2008**, 29 Suppl 2, 160-2	2

2037	[Hereditary breast cancer]. **2008**, 79, 1047-54		5
2036	The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. **2008**, 10, 78-84		26
2035	Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. **2008**, 10, 318-23		49
2034	Basal-like subtype and BRCA1 dysfunction in breast cancers. **2008**, 13, 395-400		29
2033	Hereditary breast cancer: new genetic developments, new therapeutic avenues. **2008**, 124, 31-42		233
2032	A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens. **2008**, 123, 730-6		22
2031	Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. **2008**, 18, 3942-5		35
2030	An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. **2008**, 381, 240-7		33
2029	Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. **2008**, 72, 1188-97		153
2028	Molecular diagnosis in breast cancer. **2008**, 14, 202-213		8
2027	Homologous recombination and maintenance of genome integrity: cancer and aging through the prism of human RecQ helicases. **2008**, 129, 425-40		60
2026	The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. **2008**, 15, 21-33		101
2025	Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. **2009**, 46, 132-5		22
2024	Mechanisms of chemoresistance to alkylating agents in malignant glioma. **2008**, 14, 2900-8		273
2023	Hereditary breast cancer: from molecular pathology to tailored therapies. **2008**, 61, 1073-82		35
2022	The potential of PARP inhibitors in genetic breast and ovarian cancers. **2008**, 1138, 136-45		49
2021	Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. *Nature*, **2008**, 451, 81-5	50.4	313
2020	Resistance to therapy caused by intragenic deletion in BRCA2. *Nature*, **2008**, 451, 1111-5	50.4	741

2019	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature*, **2008**, 451, 1116-20	50.4	757
2018	Translating insights from the cancer genome into clinical practice. *Nature*, **2008**, 452, 553-63	50.4	235
2017	Enabling personalized cancer medicine through analysis of gene-expression patterns. *Nature*, **2008**, 452, 564-70	50.4	415
2016	Cancer: crossing over to drug resistance. *Nature*, **2008**, 451, 1066-7	50.4	19
2015	The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. **2008**, 27, 2501-6		90
2014	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. **2008**, 99, 341-9		72
2013	BRCA1 and stem cells: tumour typecasting. **2008**, 10, 377-9		18
2012	Dam1 complexes go it alone on disassembling microtubules. **2008**, 10, 379-81		9
2011	The emerging landscape of breast cancer susceptibility. **2008**, 40, 17-22		365
2010	Bench to bedside: BRCA: from therapeutic target to therapeutic shield. **2008**, 14, 495-6		9
2009	DNA repair pathways as targets for cancer therapy. **2008**, 8, 193-204		1164
2008	Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. **2008**, 8, 180-92		827
2007	Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. **2008**, 99, 810-5		21
2006	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. **2008**, 110, 256-64		54
2005	What women with ovarian cancer think and know about genetic testing. **2008**, 111, 132-6		52
2004	Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. **2008**, 8, 17		225
2003	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. **2008**, 8, 307		92
2002	Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. **2008**, 8, 309		56

2001	Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. **2008**, 8 Suppl 4, S171-8	13
2000	BRCA1: a new genomic marker for non-small-cell lung cancer. **2008**, 9, 331-9	36
1999	Functional analysis of Drosophila melanogaster BRCA2 in DNA repair. **2008**, 7, 10-9	27
1998	Poly ADP-ribose polymerase-1: an international molecule of mystery. **2008**, 7, 1077-86	131
1997	A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. **2008**, 7, 2010-9	134
1996	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. **2008**, 8, 587-97	75
1995	4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. **2008**, 51, 6581-91	417
1994	Genetic predisposition to breast cancer: past, present, and future. **2008**, 9, 321-45	202
1993	Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. **2008**, 2, 296-316	120
1992	BRCA mutations and the risk of angiosarcoma after breast cancer treatment. **2008**, 8, 533-7	24
1991	Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment. **2008**, 7, 4	7
1990	DNA damage and repair: from molecular mechanisms to health implications. **2008**, 10, 891-937	140
1989	243 INVITED Aurora kinase inhibitors: more than one opportunity?. **2008**, 6, 79-80	
1988	244 INVITED Polo-like kinase inhibition in oncology: from bench to bedside. **2008**, 6, 80	
1987	245 INVITED PARP inhibitors in cancer treatment. **2008**, 6, 80	
1986	246 INVITED Targeting Her: Can resistance to EGFR inhibitors be overcome?. **2008**, 6, 80	
1985	Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. **2008**, 10, 216	37
1984	Molecular diversity of human breast cancer: clinical and therapeutic implications. **2008**, 10,	78

1983	Surviving breast cancer: can women expect to 'get back to normal'?. **2008**, 10,	78
1982	Identification of components of the ubiquitin system as targets for therapeutic intervention. **2008**, 10,	78
1981	Abnormal expression of p53 isoforms can be associated with poor survival in primary breast tumours. **2008**, 10,	78
1980	D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity. **2008**, 10,	78
1979	Abstracts of the meeting of the Breast Cancer Campaign. London, United Kingdom. May 13, 2008. **2008**, 10 Suppl 2, L1-P95	
1978	Primary ductal carcinoma in situmammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways. **2008**, 10,	78
1977	What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study (PIMMS). **2008**, 10,	78
1976	Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage. **2008**, 10,	78
1975	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. **2008**, 10,	78
1974	Health inequalities in breast cancer screening. **2008**, 10,	2
1973	Inhibition of apoptosis by Notch signalling in breast epithelial cells. **2008**, 10,	78
1972	Urinary and serum biomarkers of phytoestrogen exposure are not associated with breast cancer risk in the European Prospective into Cancer Norfolk study. **2008**, 10,	78
1971	Quantitative proteomics reveals proteins associated with radiotherapy resistance in breast cancer cells. **2008**, 10,	1
1970	Regulation of cyclin D1by the BRCA1BARD1 complex. **2008**, 10,	78
1969	Investigation of the roles of novel apoptosis-controlling genes in breast cancer. **2008**, 10,	78
1968	Proteomic screening of 725 antibodies simultaneously using antibody microarray technology to identify proteins associated with radiotherapy resistance in breast cancer cells. **2008**, 10,	78
1967	De novo expression of □□ integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression. **2008**, 10,	2
1966	Activation of TGF-beta signalling in breast cancer metastatic cells. **2008**, 10,	1

1965	Prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. **2008**, 10,	4
1964	Development of functional assays for BRCA1 missense mutations. **2008**, 10,	78
1963	Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer. **2008**, 10,	78
1962	Dietary patterns across the life course, mammographic density and implications for breast cancer: results from a British prospective cohort. **2008**, 10,	78
1961	Identification and definition of novel clinical phenotypes of breast cancer through consensus derived from automated clustering methods. **2008**, 10,	5
1960	Association of MMP8 gene variation with breast cancer prognosis. **2008**, 10,	1
1959	Characterization of a cytoskeletal signaling pathway underpinning CD44-initiated, integrin-mediated adhesion of breast cancer cells to bone marrow endothelium. **2008**, 10,	1
1958	Suppression of the NF-Ƀ cofactor Bcl3 inhibits mammary epithelial cell apoptosis and, in breast tumours, correlates with poor prognosis. **2008**, 10,	1
1957	Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study. **2008**, 10,	78
1956	Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1. **2008**, 10,	78
1955	Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours. **2008**, 10,	78
1954	Two functionally distinct epithelial progenitors exist within the luminal cell compartment of the mouse mammary gland. **2008**, 10,	1
1953	Chromosome translocations in breast cancer. **2008**, 10,	78
1952	TARGIT: an international trial of intraoperative versus external beam radiotherapy. **2008**, 10,	78
1951	C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. **2008**, 10,	78
1950	Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization. **2008**, 10,	1
1949	Lineage commitment in mammary epithelium is regulated by type 2 cytokines and Stat6. **2008**, 10,	0
1948	A novel role for C-terminal binding proteins in the regulation of mitotic fidelity in breast cancer cells. **2008**, 10,	78

1947	Bevacizumab resistance in breast cancer: are neuropilins the key?. **2008**, 10,	3
1946	Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer. **2008**, 10,	78
1945	Assessment of angiogenesis in the hyperplasia preinvasive, invasive breast carcinoma sequence. **2008**, 10,	78
1944	Role of poly(ADPribosyl)ation of CTCF in cancer and normal breast cells. **2008**, 10,	78
1943	Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. **2008**, 10,	78
1942	Proapoptotic protein Bid is regulated by phosphorylation during anoikis and the cell cycle. **2008**, 10,	78
1941	Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk. **2008**, 10,	78
1940	p53 isoform modulates differentially p53 transcriptional activity in response to stress. **2008**, 10,	78
1939	Investigation of immunoregulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence. **2008**, 10,	78
1938	Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models. **2008**, 10,	78
1937	Cellular localization of the proto-oncogenic p53 inhibitor AGR2 protein in breast cancer. **2008**, 10,	78
1936	Exploring the breast cancer experiences, needs and preferences of women aged 70 years and over: a study in progress. **2008**, 10,	78
1935	Diagnosed with breast cancer whilst on a family history screening programme: an exploratory qualitative study. **2008**, 10,	1
1934	TSC22 in mammary gland development and breast cancer. **2008**, 10,	78
1933	Adherence to hormone therapy in a chemoprevention randomised trial. **2008**, 10,	78
1932	Investigation into the molecular mechanism of the antiapoptotic functions of CTCF in breast cancer cells using a proteomics approach. **2008**, 10,	78
1931	Living with genetic risk of breast cancer: what have we learned?. **2008**, 10,	78
1930	MCPH1, a potential predictor for response to cancer chemotherapy. **2008**, 10,	78

1929	Homeopathy service in an NHS hospital breast cancer clinic: outcome study. **2008**, 10,	3
1928	TopBP1 contains transcriptional regulatory domains and regulates gene pathways involved in breast cancer. **2008**, 10,	78
1927	Identification of proteins associated with radiotherapy resistance in breast cancer cells: a combined proteomic and microarray screening approach. **2008**, 10,	78
1926	PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer. **2008**, 10,	78
1925	Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells. **2008**, 10,	78
1924	Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer. **2008** , 10,	3
1923	Identification and role of migration stimulating factor isoforms in breast carcinomas. **2008**, 10,	78
1922	Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation. **2008**, 10,	0
1921	Understanding and exploiting changes in O-linked glycosylation in breast cancer. **2008**, 10,	78
1920	Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes. **2008**, 10,	78
1919	High-throughput optical proteomics and breast cancer patient profiling: novel applications to individualise prognosis and treatment. **2008**, 10,	78
1918	Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level. **2008**, 10,	78
1917	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. **2008**, 10,	2
1916	Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor. **2008**, 10,	78
1915	Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR. **2008**, 10,	1
1914	CD44 signalling increases cathepsin K and MT1MMP expression to potentiate breast cancer cell invasion through collagen I. **2008**, 10,	1
1913	Identification of genes involved in the formation of lymph node metastasis from human tumour xenograft models of breast cancer. **2008**, 10,	78
1912	Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival. **2008**, 10,	1

1911	Lymphovascular invasion in breast cancer: improved methods of detection and clinical significance. **2008**, 10,	78
1910	Brk expression may affect the differentiation status of breast cancer cells. **2008**, 10,	78
1909	Role of CLEVER-1 in breast cancer metastasis. **2008**, 10,	78
1908	Actions of IGF-I are differentially regulated by fatty acids in normal and breast cancer epithelial cells. **2008**, 10,	78
1907	Interactions between BRCA2 protein and the meiosis-specific recombinase DMC1. **2008**, 10,	78
1906	ZNF366 is a novel corepressor for estrogen receptor alpha that mediates its effects through interaction with CtBP. **2008**, 10,	78
1905	Cambridge Breast Intensity Modulated Radiotherapy Trial: dosimetry results for 1,139 patients. **2008**, 10,	78
1904	Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?. **2008**, 10,	78
1903	Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity. **2008**, 10,	1
1902	Topoisomerase II expression as a determinant of chromosomal radiosensitivity and possible susceptibility in breast cancer. **2008**, 10,	78
1901	RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours. **2008**, 10,	78
1900	Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. **2008**, 10,	78
1899	Stromal fibroblasts with nuclear □catenin are present within breast tumours and increase proliferation and invasion of epithelial breast cancer cells. **2008**, 10,	78
1898	Altered myoepithelial cell expression and function in cancer-containing breasts. **2008**, 10,	78
1897	NRG1is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. **2008**, 10,	1
1896	An exploration of the management of menopausal symptoms for women with a diagnosis of breast cancer: lay and professional experiences and expectations. **2008**, 10,	1
1895	Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers. **2008**, 10,	78
1894	Breast cancer and environmental risk factors: an appraisal of the scientific evidence. **2008**, 10,	4

1893	From association to cause: fine mapping of the TNRC9gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer. **2008**, 10,	1
1892	Inhibitor of apoptosis proteins as a therapeutic target in breast cancer. **2008**, 10,	78
1891	Discrepancies and challenge of ductal carcinoma in situfor health professionals. **2008**, 10,	78
1890	'The sooner the better' or 'too much too soon'? A pilot prospective longitudinal study to evaluate quality of life and body image following immediate latissimus dorsi breast reconstruction. **2008**, 10,	78
1889	Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer. **2008**, 10,	78
1888	Multicentre study of CASP8 polymorphisms in breast cancer. **2008**, 10,	78
1887	Investigating h-Prune activation of Wnt signalling in breast cancer. **2008**, 10,	78
1886	Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer. **2008**, 10,	78
1885	'More positive about mammography' Reactions of women to a false positive recall: a qualitative study of women at risk of familial breast cancer. **2008**, 10,	78
1884	Regulation of estrogen receptor beta by 5' untranslated regions in breast carcinogenesis. **2008**, 10,	78
1883	Expression analysis of novel biomarkers for breast cancer. **2008**, 10,	2
1882	The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy. **2008**, 10,	78
1881	Use of BRCA1 protein:protein interactions to classify cancer risk. **2008**, 10,	2
1880	Ovarian Cancer. **2008**,	2
1879	Methed-up FOXOs can't in-Akt-ivate. **2008**, 32, 160-2	2
1878	SIRTing through breast cancer is just a survivin' game. **2008**, 32, 159-60	5
1877	Toward specific functions of poly(ADP-ribose) polymerase-2. **2008**, 14, 169-78	127
1876	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. **2008**, 29, 515-9	45

1875	Amplifying tumour-specific replication lesions by DNA repair inhibitors - a new era in targeted cancer therapy. **2008**, 44, 921-7	27
1874	Targeted therapies in breast cancer: where are we now?. **2008**, 44, 2781-90	71
1873	What is triple-negative breast cancer?. **2008**, 44, 2799-805	230
1872	Can genetic testing guide treatment in breast cancer?. **2008**, 44, 2774-80	20
1871	DNA repair deficiency as a therapeutic target in cancer. **2008**, 18, 80-6	144
1870	The Yin and Yang of treating BRCA-deficient tumors. **2008**, 132, 919-20	8
1869	Targeted therapy for cancer using PARP inhibitors. **2008**, 8, 363-9	237
1868	Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. **2008**, 8, 359-62	25
1867	A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. **2008**, 27, 1368-77	257
1866	Ovarian cancer: can we reverse drug resistance?. **2008**, 622, 153-67	8
1865	Authors reply to Dr. Baltoyiannis and colleagues letter. **2008**, 86, 288	
1864	The value of Day 1 imaging following LDR prostate brachytherapy. **2008**, 86, 288-9; author reply 289-90	5
1863	Linking contralateral breast cancer with genetics. **2008**, 86, 139-41	65
1862	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. **2008**, 88, 258-68	114
1861	The potential role and application of PARP inhibitors in cancer treatment. **2009**, 89, 23-40	80
1860	Breast cancer stem cells and tumor suppressor genes. **2008**, 107, 751-66	12
1859	Basal-like breast cancer: a critical review. **2008**, 26, 2568-81	657
1858	Target validation to biomarker development: focus on RNA interference. **2008**, 12, 63-70	5

1857	Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. **2008**, 68, 3243-50	262
1856	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. **2008**, 12, 1123-37	16
1855	Modern cancer drug discovery: integrating targets, technologies and treatments. **2008**, 3-38	3
1854	Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. **2008**, 14, 3916-25	258
1853	Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. **2008**, 68, 257-65	53
1852	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. **2008**, 105, 17079-84	707
1851	Platinum-based chemotherapy in triple-negative breast cancer. **2008**, 19, 1847-52	167
1850	Breast Cancer. **2008**,	3
1849	Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. **2008**, 19, 696-705	63
1848	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. **2008**, 26, 20-5	262
1847	Platinum resistance: the role of DNA repair pathways. **2008**, 14, 1291-5	565
1846	Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. **2008**, 6, 282-90	57
1845	Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. **2008**, 68, 3169-77	132
1844	WRN is required for ATM activation and the S-phase checkpoint in response to interstrand cross-link-induced DNA double-strand breaks. **2008**, 19, 3923-33	68
1843	Translational epigenetics: clinical approaches to epigenome therapeutics for cancer. **2008**, 3, 107-12	10
1842	Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. **2008**, 7, 2647-53	22
1841	Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. **2008**, 7, 2987-90	21
1840	How do real tumors become resistant to cisplatin?. **2008**, 7, 1353-9	168

1839	Topoisomerase levels determine chemotherapy response in vitro and in vivo. **2008**, 105, 9053-8	222
1838	A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. **2008**, 26, 3785-90	659
1837	Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications. **2008**, 68, 9973-81	15
1836	Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress. **2008**, 68, 2699-707	49
1835	PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. **2008**, 283, 1197-208	369
1834	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. **2008**, 26, 4282-8	435
1833	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. **2008**, 14, 7917-23	309
1832	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. **2008**, 26, 5530-6	367
1831	Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. **2008**, 26, 3259-67	56
1830	PARP inhibitors and cancer therapy - early results and potential applications. **2008**, 81 Spec No 1, S2-5	15
1829	Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. **2008**, 81 Spec No 1, S6-11	34
1828	Principles of Molecular Oncology. **2008**,	1
1827	PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. **2008**, 29, 1911-9	23
1826	XRCC1 protects against the lethality of induced oxidative DNA damage in nondividing neural cells. **2008**, 36, 5111-21	30
1825	Non-conservative homologous recombination in human B lymphocytes is promoted by activation-induced cytidine deaminase and transcription. **2008**, 36, 5591-601	7
1824	A syngeneic variance library for functional annotation of human variation: application to BRCA2. **2008**, 68, 5023-30	59
1823	Introducing new molecular technologies into routine clinical cancer care. What new technology and what for?. **2008**, 19 Suppl 7, vii173-6	
1822	Critical molecular abnormalities in high-grade serous carcinoma of the ovary. **2008**, 10, e22	42

1821	Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?. **2008**, 26, 9-10	27
1820	Hereditary Gynecologic Cancer. **2008**,	2
1819	Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. **2008**, 68, 9771-8	20
1818	The histone subcode: poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1beta and the heterochromatin protein HP1alpha. **2008**, 22, 3853-65	50
1817	A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. **2008**, 283, 4105-14	139
1816	Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. **2008**, 17, 1013-28	41
1815	Pharmakogenetik in der antihormonellen Therapie von Patientinnen mit einem Mammakarzinom. **2008**, 68, 1192-1200	1
1814	Helicases as prospective targets for anti-cancer therapy. **2008**, 8, 390-401	16
1813	Impact of basal-like breast carcinoma determination for a more specific therapy. **2008**, 75, 95-103	25
1812	DNA repair proteins as molecular targets for cancer therapeutics. **2008**, 8, 417-25	73
1811	Strategies to enhance radiosensitivity in breast cancer. **2008**, 11,	
1810	Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. **2008**, 7, 1004-5	27
1809	Resistance to Chemotherapy Drugs. 263-281	
1808	Identification of genes differentially expressed in mouse fetuses from streptozotocin-induced diabetic pregnancy by cDNA subtraction. **2008**, 55, 317-23	13
1807	Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors. **2008**, 93, 1886-9	15
1806	Drug resistance caused by reversion mutation. **2008**, 68, 10021-3	76
1805	Invited Speakers Abstracts. **2008**, 3, S179-S204	
1804	Triple negative breast cancer: current understanding of biology and treatment options. **2008**, 20, 40-6	50

1803	Hereditary breast cancer: from bench to bedside. **2008**, 20, 605-13	18
1802	Therapeutic strategies for triple-negative breast cancer. **2008**, 14, 343-51	58
1801	. **2008**,	9
1800	Preclinical pharmacology and in vivo models. **2008**, 39-52	0
1799	DNA Repair Pathways and Human Cancer. **2008**, 39-55	1
1798	Inhibition of DNA repair as a therapeutic target. **2008**, 284-304	
1797	Conference Reports. **2009**, 37, 445-450	
1796	Predicting response to radiotherapy: Evolutions and revolutions. **2009**, 85, 825-836	31
1795	PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. **2009**, 15, 2269-80	128
1794	Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. **2009**, 106, 3276-81	103
1793	Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. **2009**, 15, 6314-20	156
1792	Update on genetic predisposition to breast cancer. **2009**, 9, 1103-13	10
1791	Preclinical mouse models for BRCA1-associated breast cancer. **2009**, 101, 1651-7	36
1790	Bringing DNA repair in tumors into focus. **2009**, 15, 3241-3	15
1789	Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment. **2009**, 20, 114-23	49
1788	Elevated poly-(ADP-ribose)-polymerase activity sensitizes retinoblastoma-deficient cells to DNA damage-induced necrosis. **2009**, 7, 1099-109	16
1787	Third consensus on medical treatment of metastatic breast cancer. **2009**, 20, 1771-85	139
1786	CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. **2009**, 15, 5145-53	149

1785	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. **2009**,	2
1784	Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. **2009**, 8, 2243-54	92
1783	BRCA1/2-associated and sporadic breast cancers: fellow travelers or not?. **2009**, 2, 100-3	3
1782	The future of targeted therapies in ovarian cancer. **2009**, 14, 706-16	45
1781	Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers. **2009**, 27, 3894-900	6
1780	Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells. **2009**, 76, 108-16	20
1779	Molecular biomarkers for predicting chemotherapy response in lung cancer. **2009**, 3, 621-9	
1778	Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. **2009**, 15, 1853-9	79
1777	Targeting cancer-specific synthetic lethality in double-strand DNA break repair. **2009**, 8, 1872-6	15
1776	Enhancing radiosensitivity: targeting the DNA repair pathways. **2009**, 8, 665-70	47
1775	Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. **2009**, 9, 101-17	37
1774	Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy. **2009**, 4, 19-28	8
1773	Das tripelnegative/basale Mammakarzinom. **2009**, 69, 309-315	
1772	Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. **2009**, 8, 2004-9	20
1771	Pharmakogenetik in der antihormonellen Therapie von Patientinnen mit einem Mammakarzinom. **2009**, 6, 104-112	
1770	Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. **2009**, 18, 1467-77	12
1769	Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. **2009**, 5, 713-26	32
1768	Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. **2009**, 11, 624-8	15

1767	Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. **2009**, 5, 1363-70	21
1766	Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. **2009**, 7, 1686-92	76
1765	BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. **2009**, 27, 433-8	160
1764	Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. **2009**, 69, 3850-5	89
1763	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. **2009**, 46, 811-7	65
1762	ASCO 2009: What's New in Breast Cancer Therapy?. **2009**, 4, 268-271	
1761	Exploiting synthetic lethal interactions for targeted cancer therapy. **2009**, 8, 3112-9	87
1760	Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. **2009**, 20, 609-14	30
1759	Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. **2009**, 15, 6367-77	34
1758	Epigenetic deregulation of DNA repair and its potential for therapy. **2009**, 15, 5026-31	49
1757	Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. **2009**, 8, 844-54	26
1756	Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. **2009**, 94, 638-46	67
1755	INTS3 controls the hSSB1-mediated DNA damage response. **2009**, 187, 25-32	67
1754	Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. **2009**, 27, 3764-71	80
1753	Mammalian Rif1 contributes to replication stress survival and homology-directed repair. **2009**, 187, 385-98	101
1752	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. **2009**, 69, 3589-96	114
1751	ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. **2009**, 15, 7277-90	117
1750	The DNA Damage Response: Implications on Cancer Formation and Treatment. **2009**,	3

1749	XRCC1 interacts with the p58 subunit of DNA Pol alpha-primase and may coordinate DNA repair and replication during S phase. **2009**, 37, 3177-88	24
1748	Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. **2009**, 668, 54-72	121
1747	Parp2 is required for the differentiation of post-meiotic germ cells: identification of a spermatid-specific complex containing Parp1, Parp2, TP2 and HSPA2. **2009**, 315, 2824-34	18
1746	BRCA1 and implications for response to chemotherapy in ovarian cancer. **2009**, 113, 134-42	70
1745	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. **2009**, 115, 193-8	24
1744	Genetic characterization of breast cancer and implications for clinical management. **2009**, 13, 4090-103	31
1743	Targeting the DNA damage response for cancer therapy. **2009**, 8, 1153-65	60
1742	PARP inhibition during alkylation-induced genotoxic stress signals a cell cycle checkpoint response mediated by ATM. **2009**, 8, 1264-72	18
1741	NBS1 cooperates with homologous recombination to counteract chromosome breakage during replication. **2009**, 8, 1363-70	7
1740	Therapeutic options for triple-negative breast cancers with defective homologous recombination. **2009**, 1796, 266-80	22
1739	Regulation of the activity and expression of ERK8 by DNA damage. **2009**, 583, 680-4	24
1738	PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. **2009**, 47, 13-26	145
1737	Histopathological criteria and selection algorithms for BRCA1 genetic testing. **2009**, 189, 105-11	13
1736	Targeting the molecular defect in BRCA-deficient tumors for cancer therapy. **2009**, 16, 89-90	12
1735	New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells. **2009**, 625, 151-5	48
1734	Management of recurrent ovarian carcinoma: current status and future directions. **2009**, 36, 112-25	71
1733	Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics. **2009**, 36, S42-51	11
1732	Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. **2010**, 32, 381-91	52

1731	The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. **2009**, 124, 806-15	79
1730	Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. **2009**, 115, 899-908	36
1729	Hitting the bull's eye: novel directed cancer therapy through helicase-targeted synthetic lethality. **2009**, 106, 758-63	21
1728	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. **2009**, 1, 315-22	500
1727	Converting cancer mutations into therapeutic opportunities. **2009**, 1, 297-9	6
1726	La recherche clinique dans le domaine du cancer du sein: □at des lieux et perspectives. **2009**, 11, 319-324	
1725	Induction of apoptosis by the inhibitors of poly(ADP-ribose)polymerase in HeLa cells. **2009**, 320, 15-23	19
1724	Targeted therapy of metastatic breast cancer. **2009**, 11, 643-50	27
1723	Abstracts 2009. **2009**, 10, 1-213	
1722	Emergence of truly "individualized" therapy: the poly (adenosine diphosphate-ribose) polymerase inhibitors. **2009**, 11, 414-6	
1721	Clinical importance of DNA repair inhibitors in cancer therapy. **2009**, 2, 9-14	10
1720	Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. **2009**, 16, 275-80	26
1719	Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. **2009**, 16, 268-74	9
1718	Molecular classes of breast cancer and their clinical relevance. **2009**, 1, 183-189	
1717	Mamma- und Ovarialkarzinome bei BRCA1- oder BRCA2-Mutationstr□gerinnen. **2009**, 42, 189	
1716	Risiko f□ Brust- und Eierstockkrebs. **2009**, 42, 847-852	
1715	DNA damage response pathways in tumor suppression and cancer treatment. **2009**, 33, 661-6	68
1714	Genomic instability and the selection of treatments for cancer. **2010**, 220, 281-9	46

1713	BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?. **2009**, 2, 14		19
1712	Fragile gene product, Fhit, in oxidative and replicative stress responses. **2009**, 100, 1145-50		31
1711	From darkness to light with biomarkers in early clinical trials of cancer drugs. **2009**, 85, 131-3		28
1710	PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. **2009**, 28, 2601-15		426
1709	The DNA-damage response in human biology and disease. *Nature*, **2009**, 461, 1071-8	50.4	3641
1708	Beyond chemotherapy: targeted therapies in ovarian cancer. **2009**, 9, 167-81		408
1707	Cell cycle, CDKs and cancer: a changing paradigm. **2009**, 9, 153-66		2453
1706	Awakening guardian angels: drugging the p53 pathway. **2009**, 9, 862-73		713
1705	Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. **2009**, 28, 1465-70		57
1704	Methodological approaches in application of synthetic lethality screening towards anticancer therapy. **2009**, 100, 1213-8		24
1703	Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. **2009**, 22, 291-7		19
1702	T1 N0 triple negative breast cancer: a bad actor. **2009**, 15, 451-3		
1701	4-Substituted 5-nitroisoquinolin-1-ones from intramolecular Pd-catalysed reaction of N-(2-alkenyl)-2-halo-3-nitrobenzamides. **2009**, 65, 4751-4765		13
1700	Role of poly(ADP-ribose) polymerase in sulfur mustard toxicity. **2009**, 263, 20-5		42
1699	Identifying druggable disease-modifying gene products. **2009**, 13, 549-55		68
1698	Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance. **2009**, 73, 1219-27		33
1697	Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. **2009**, 19, 4196-200		40
1696	Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. **2009**, 16, 1771-82		80

1695	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. **2009**, 361, 123-34	2786
1694	Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. **2009**, 4, 461-87	155
1693	Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. **2009**, 52, 3108-11	79
1692	Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. **2009**, 20, 1319-29	1005
1691	Going ape as an approach to cancer therapeutics. **2009**, 11, 651-68	86
1690	Genetic issues in patients with breast cancer. **2009**, 18, 53-71, viii	5
1689	Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. **2009**, 35, 590-6	39
1688	PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. **2009**, 12, 153-6	67
1687	Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?. **2009**, 45, 2768-81	61
1686	Principles of cancer therapy: oncogene and non-oncogene addiction. **2009**, 136, 823-37	1328
1685	Ovarian carcinoma pathology and genetics: recent advances. **2009**, 40, 1213-23	181
1684	Diverse molecular pathways in ovarian cancer and their clinical significance. **2009**, 62, 270-5	34
1683	Triple-negative breast cancer: novel therapies and new directions. **2009**, 63, 269-74	41
1682	Necrosis: Molecular Mechanisms and Physiological Roles. **2009**, 599-633	1
1681	Targeting the DNA damage response in cancer. **2009**, 109, 2929-50	114
1680	Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. **2009**, 65, 144-9	9
1679	BRCA1 involvement in toxicological responses and human cancer etiology. **2009**, 188, 77-83	12
1678	Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer. **2009**, 27-38	

1677	4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. **2009**, 52, 7122-31	45
1676	Synthetic lethality--a new direction in cancer-drug development. **2009**, 361, 189-91	170
1675	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. **2009**, 9 Suppl 2, S73-81	424
1674	Getting Personal! The Treatment of Epithelial Ovarian Cancer. **2009**, 2, 9-11	
1673	DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. **2009**, 109, 2951-73	41
1672	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. **2009**, 52, 7170-85	215
1671	Systematic mapping of genetic interaction networks. **2009**, 43, 601-25	206
1670	The Fanconi anemia-BRCA Pathway and Cancer. **2009**, 367-414	
1669	Novel therapeutic targets. **2009**, 149, 63-84	2
1668	Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. **2009**, 206, 1047-56	138
1667	Triple-negative/basal-like breast cancer: review. **2009**, 41, 40-7	204
1666	Molecular, Clinical and Environmental Toxicology. **2009**,	10
1665	A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. **2009**, 11, R78	42
1664	Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer. **2009**, 11, 108	4
1663	Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. **2009**, 11, 208	10
1662	Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?. **2009**, 19, 1377-400	34
1661	Triple-negative breast cancer--current status and future directions. **2009**, 20, 1913-27	416
1660	Synthetic lethality: a framework for the development of wiser cancer therapeutics. **2009**, 1, 99	64

1659	Novel therapeutics in breast cancer□looking to the future. **2009**, 3, 189-205	6
1658	DNA Double Strand Break Repair: Mechanisms and Therapeutic Potential. **2009**, 157-177	
1657	Development of PARP inhibitors in oncology. **2009**, 18, 31-43	46
1656	PARP inhibitors: making progress toward individualized treatment in breast cancer. **2009**, 6, 342-343	
1655	How the fanconi anemia pathway guards the genome. **2009**, 43, 223-49	426
1654	Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. **2009**, 45 Suppl 1, 11-26	50
1653	Triple negative breast cancers: clinical and prognostic implications. **2009**, 45 Suppl 1, 27-40	173
1652	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor. **2009**, 52, 868-77	68
1651	Pharmacotherapy of triple-negative breast cancer. **2009**, 10, 2081-93	26
1650	Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. **2009**, 52, 6803-13	84
1649	Triple-Negative Breast Carcinoma. **2009**, 2, 247-61	3
1648	DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. **2009**, 11, 683-91	75
1647	New therapeutic agents in ovarian cancer. **2009**, 21, 44-53	16
1646	Triple negative breast carcinomas: similarities and differences with basal like carcinomas. **2009**, 17, 483-94	17
1645	Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. **2009**, 15, 406-20	133
1644	Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. **2009**, 34, 861-72	10
1643	Gene expression profiling of archival tongue squamous cell carcinomas provides sub-classification based on DNA repair genes. **2009**, 35, 1321-30	11
1642	The DNA-damage response: new molecular insights and new approaches to cancer therapy. **2009**, 37, 483-94	41

1641	DNA-repair pathway inhibitors for the treatment of ovarian cancer. **2009**,	3
1640	Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients?. **2009**, 19, 1501-4	6
1639	RING finger E(3) ubiquitin ligases: structure and drug discovery. **2009**, 15, 3716-31	46
1638	Breast cancer in the personal genomics era. **2010**, 11, 146-61	56
1637	Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. **2010**, 16, 83-90	26
1636	Inducing synthetic lethality using PARP inhibitors. **2010**, 5, 192-5	11
1635	High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. **2010**, 115, 49-54	12
1634	PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. **2010**, 22, 473-80	31
1633	Triple-negative breast cancer: a short review. **2010**, 33, 637-45	99
1632	BRCA gene structure and function in tumor suppression: a repair-centric perspective. **2010**, 16, 39-47	49
1631	Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. **2010**, 16, 48-52	38
1630	The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. **2010**, 22, 67-71	21
1629	Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. **2010**, 10, 626-39	14
1628	Poly ADP-ribose polymerase inhibitors: science and current clinical development. **2010**, 22, 567-72	5
1627	DNA-repair pathway inhibitors for the treatment of ovarian cancer. **2010**, CD007929	8
1626	A review of triple-negative breast cancer. **2010**, 17, 173-6	152
1625	??????????????????. **2010**, 7, 18-20	
1624	Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. **2010**, 20, 704-16	22

1623	Personalizing therapy for ovarian cancer. **2010**, 7, 229-239	1
1622	Triple-negative breast cancers: unique clinical presentations and outcomes. **2010**, 17 Suppl 3, 384-90	65
1621	Corchorusin-D, a saikosaponin-like compound isolated from Corchorus acutangulus Lam., targets mitochondrial apoptotic pathways in leukemic cell lines (HL-60 and U937). **2010**, 66, 709-19	17
1620	[Hereditary breast and ovarian cancers]. **2010**, 31, 438-44	1
1619	Targeting poly(ADP-ribose) polymerase activity for cancer therapy. **2010**, 67, 3649-62	52
1618	Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. **2010**, 67, 3683-97	53
1617	Targeting abnormal DNA double strand break repair in cancer. **2010**, 67, 3699-710	49
1616	Das familiäre Mammakarzinom. **2010**, 43, 79-86	
1615	BRCA-Aktivität beim triple-negativen Mammakarzinom. **2010**, 43, 1002-1007	
1614	Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. **2010**, 128, 567-75	10
1613	Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. **2010**, 15, 235-41	15
1612	Research progress in triple-negative breast cancer. **2010**, 9, 239-242	3
1611	Triple-negative breast cancer. **2010**, 160, 174-81	23
1610	Metastatic breast cancer – ASCO 2010. **2010**, 3, 159-162	0
1609	Triple Negative Breast Cancer. **2010**, 3, 185-189	
1608	Exploring the Concept of Synthetic Lethality to Improve Therapeutic Options for Patients with Breast Cancer. **2010**, 2, 1-3	1
1607	PARP Inhibitors for the Treatment and Prevention of Breast Cancer. **2010**, 2, 190-197	22
1606	The role of BRCA1 in DNA damage response. **2010**, 1, 117-23	131

1605	Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook. **2010**, 27, 531-9	20
1604	Classification of ovarian carcinomas based on pathology and molecular genetics. **2010**, 12, 783-7	7
1603	Emerging therapies in castrate-resistant prostate cancer. **2010**, 11, 152-8	14
1602	Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. **2010**, 119, 685-99	70
1601	Health disparities in breast cancer: biology meets socioeconomic status. **2010**, 121, 281-92	76
1600	DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. **2010**, 123, 189-96	57
1599	DNA repair pathways and their implication in cancer treatment. **2010**, 29, 677-85	23
1598	Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. **2010**, 37, 384-401	31
1597	Drug development for cancer chemoprevention: focus on molecular targets. **2010**, 37, 345-58	50
1596	Aberrant expression of alternative DNA polymerases: a source of mutator phenotype as well as replicative stress in cancer. **2010**, 20, 312-9	32
1595	Enhancing radiotherapy through a greater understanding of homologous recombination. **2010**, 20, 267-273.e3	18
1594	Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. **2010**, 20, 274-81	104
1593	DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. **2010**, 20, 217-22	57
1592	DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. **2010**, 20, 402-9	126
1591	Novel treatment approaches for triple-negative breast cancer. **2010**, 10 Suppl 1, E16-22	19
1590	Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. **2010**, 10 Suppl 2, S7-19	6
1589	Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. **2010**, 10, 493	5
1588	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. **2010**, 10, 654	46

1587	Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. **2010**, 10, 90	31
1586	Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. **2010**, 9, 929-36	41
1585	Coping with DNA double strand breaks. **2010**, 9, 1256-63	79
1584	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. **2010**, 15, 88-97	57
1583	Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". **2010**, 80, 666-73	48
1582	Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. **2010**, 80, 755-61	28
1581	Fine tuning chemotherapy to match BRCA1 status. **2010**, 80, 647-53	11
1580	Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. **2010**, 19, 246-8	57
1579	DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. **2010**, 17, 235-48	158
1578	Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. **2010**, 18, 499-509	126
1577	Targeting cancer cells through autophagy for anticancer therapy. **2010**, 22, 246-51	97
1576	Achievements and unmet needs in the management of advanced ovarian cancer. **2010**, 117, 152-8	68
1575	Targeted trials in ovarian cancer. **2010**, 119, 151-6	26
1574	SGO White Paper on ovarian cancer: etiology, screening and surveillance. **2010**, 119, 7-17	116
1573	Repair of DNA interstrand cross-links during S phase of the mammalian cell cycle. **2010**, 51, 540-51	23
1572	The DNA damage response--repair or despair?. **2010**, 51, 879-89	27
1571	DNA repair and personalized breast cancer therapy. **2010**, 51, 897-908	16
1570	Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. **2010**, 2, 130-42	51

1569	Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. **2010**, 51, 255-66	54
1568	Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). **2010**, 20, 1094-9	14
1567	Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. **2010**, 20, 1100-5	10
1566	Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors. **2010**, 20, 488-92	13
1565	Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). **2010**, 20, 448-52	8
1564	Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. **2010**, 76, 615-23	20
1563	Biology-driven cancer drug development: back to the future. **2010**, 8, 38	30
1562	DNA double-strand break signaling and human disorders. **2010**, 1, 15	53
1561	Inhibition of poly (ADP-Ribose) polymerase-1 in telomerase deficient mouse embryonic fibroblasts increases arsenite-induced genome instability. **2010**, 1, 5	12
1560	Dominance and gene dosage balance in health and disease: why levels matter!. **2010**, 220, 174-85	48
1559	Our changing view of the genomic landscape of cancer. **2010**, 220, 231-43	64
1558	Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. **2010**, 17, 1247-54	217
1557	Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice. **2010**, 29, 2877-83	42
1556	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. **2010**, 29, 6280-93	88
1555	Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. **2010**, 29, 6085-98	110
1554	Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. **2010**, 103, 1192-200	43
1553	Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. **2010**, 29, 3130-9	253
1552	DNA end resection by CtIP and exonuclease 1 prevents genomic instability. **2010**, 11, 962-8	98

1551	Translating cancer research into targeted therapeutics. *Nature*, **2010**, 467, 543-9	50.4	269
1550	Translational research: Talking up translation. *Nature*, **2010**, 463, 422-3	50.4	1
1549	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. **2010**, 42, 874-9		277
1548	PARP inhibition: PARP1 and beyond. **2010**, 10, 293-301		985
1547	Envisioning the future of early anticancer drug development. **2010**, 10, 514-23		232
1546	Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice. **2010**, 77, 350-4		9
1545	Challenges in pharmacology of anti-cancer drugs - the search for addictions. **2010**, 1, 120		2
1544	Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. **2010**, 51, 295-301		30
1543	Targeted therapies in epithelial ovarian cancer. **2010**, 2, 88-113		11
1542	Targeted therapy in ovarian cancer. **2010**, 2010, 740472		22
1541	The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. **2010**, 2010, 151750		19
1540	Targeted therapies in epithelial ovarian cancer. **2010**, 2010, 314326		17
1539	Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. **2010**, 2010, 740968		37
1538	BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer. **2010**, 2010, 891059		14
1537	Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. **2010**, 5, e10767		51
1536	PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. **2010**, 57, 401-5		5
1535	Assembling an orchestra: Fanconi anemia pathway of DNA repair. **2010**, 15, 1131-49		9
1534	Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. **2010**, 10, 144-52		8

1533	New developments in treatment of ovarian carcinoma: focus on trabectedin. **2010**, 233	
1532	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. **2010**, 31, 961-7	193
1531	Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. **2010**, 12, 245-59	221
1530	Improving surveillance and quality of life of BRCA mutation carriers. **2010**, 28, e376-7	1
1529	Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1. **2010**, 30, 2341-52	27
1528	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. **2010**, 70, 7970-80	128
1527	Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. **2010**, 16, 4532-42	203
1526	The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. **2010**, 285, 18877-87	113
1525	Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. **2010**, 70, 8088-96	64
1524	DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. **2010**, 16, 5796-804	26
1523	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. **2010**, 28, 3555-61	371
1522	Cancers du sein mtastatiques « triples ngatifs ». Critres cliniques et biologiques additionnels ncessaires pour prendre une dcision thrapeutique. Stratgies thrapeutiques, place des anti-angiogniques et nouvelles thrapeutiques ciblles. **2010**, 233-242	
1521	The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. **2010**, 116, 4578-87	233
1520	Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. **2010**, 16, 4527-31	72
1519	Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. **2010**, 9, 1775-87	101
1518	TUMOR SUPPRESSOR PATHWAYS AND CELLULAR ORIGINS OF BREAST CANCER: NEW COMPLEXITIES AND NEW HOPES. **2010**, 01, 1-16	2
1517	ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. **2010**, 9, 347-57	153
1516	Metnase promotes restart and repair of stalled and collapsed replication forks. **2010**, 38, 5681-91	49

1515	Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia. **2010**, 70, 5912-22	30
1514	BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. **2010**, 28, e563-4; author reply e565-6	129
1513	p53-based cancer therapy. **2010**, 2, a001222	165
1512	Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. **2010**, 70, 5389-98	173
1511	Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. **2010**, 70, 8706-14	31
1510	Therapeutic targeting of the DNA mismatch repair pathway. **2010**, 16, 5107-13	110
1509	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. **2010**, 16, 4702-10	120
1508	Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. **2010**, 1, 812-21	167
1507	Error-prone translesion synthesis mediates acquired chemoresistance. **2010**, 107, 20792-7	158
1506	PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. **2010**, 285, 8054-60	109
1505	New drugs for breast cancer. **2010**, 96, 111-29	6
1504	Homologous recombination in cancer development, treatment and development of drug resistance. **2010**, 31, 955-60	188
1503	Cancer du sein en situation m□astatique. **2010**,	
1502	Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. **2010**, 10, 81-8	42
1501	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. **2010**, 107, 12629-33	372
1500	Susceptibility pathways in Fanconi's anemia and breast cancer. **2010**, 362, 1909-19	282
1499	Prognostic factors for local recurrence following breast-conserving treatment in young women. **2010**, 10, 1215-27	4
1498	Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. **2010**, 16, 4517-26	79

1497	Reply to J. Veeck et al. **2010**, 28, e565-e566	13
1496	Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. **2010**, 107, 2201-6	161
1495	PARP1 suppresses homologous recombination events in mice in vivo. **2010**, 38, 7538-45	23
1494	Early oncology clinical trial design in the era of molecular-targeted agents. **2010**, 6, 1339-52	10
1493	Systems Pharmacology in Cancer. **2010**, 377-397	
1492	PALB2/FANCN: recombining cancer and Fanconi anemia. **2010**, 70, 7353-9	148
1491	Redox regulation of DNA repair: implications for human health and cancer therapeutic development. **2010**, 12, 1247-69	95
1490	Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. **2010**, 285, 14565-71	98
1489	Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. **2010**, 70, 8045-54	176
1488	"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. **2010**, 16, 4553-60	91
1487	Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. **2010**, 107, 20786-91	144
1486	A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. **2010**, 16, 99-108	67
1485	PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. **2010**, 6, 485-6	18
1484	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. **2010**, 28, 2512-9	737
1483	Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. **2010**, 18, 1599-605	17
1482	Molecular targets and clinical cancer risk reductive interventions. **2010**, 95, 351-75	
1481	Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. **2010**, 6, e1000995	29
1480	Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination. **2010**, 6, e1001160	36

1479	Beyond triple-negative breast cancer: the need to define new subtypes. **2010**, 10, 1197-213	17
1478	PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. **2010**, 2, 53ra75	190
1477	Targeting the DNA double strand breaks repair for cancer therapy. **2010**, 17, 2017-48	18
1476	Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors. **2010**, 9, 4052-7	41
1475	Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. **2010**, 9, 2118-23	11
1474	Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. **2010**, 79, 324-30	50
1473	A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. **2010**, 16, 6159-68	240
1472	Pathology of hereditary breast cancer. **2010**, 23 Suppl 2, S46-51	57
1471	Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. **2010**, 28, E4	12
1470	Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. **2010**, 31, 1172-80	39
1469	DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer. **2010**, 6, 1031-42	41
1468	Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. **2010**, 7, 273-84	13
1467	Aktuelle Empfehlungen zur Pr□vention und Therapie des famili□en Mammakarzinoms. **2010**, 70, 634-639	
1466	Strategies towards more effective anticancer therapies: targeting DNA damage response pathways. **2010**, 3, 103-15	2
1465	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. **2010**, 70, 5457-64	189
1464	BRCA1 regulation of base excision repair pathway. **2010**, 9, 2471-2	15
1463	Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. **2010**, 12, e22	25
1462	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. **2010**, 28, 3570-6	290

1461	BRCA mutations in the management of breast cancer: the state of the art. **2010**, 7, 702-7	125
1460	The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. **2010**, 108, 73-112	790
1459	Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. **2010**, 10, 1125-36	30
1458	Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. **2011**, 188, 21-47	19
1457	The role of BRCA mutation testing in determining breast cancer therapy. **2010**, 7, 708-17	74
1456	Triple-negative breast cancer. **2010**, 12 Suppl 2, S3	165
1455	Making the best of PARP inhibitors in ovarian cancer. **2010**, 7, 508-19	85
1454	Genomic instability in breast cancer: pathogenesis and clinical implications. **2010**, 4, 255-66	91
1453	Histological types of breast cancer: how special are they?. **2010**, 4, 192-208	255
1452	Molecular basis for therapy resistance. **2010**, 4, 284-300	36
1451	Triple-negative breast cancer: present challenges and new perspectives. **2010**, 4, 209-29	212
1450	Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. **2010**, 7, 139-47	132
1449	Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. **2010**, 9, 127	20
1448	Treatment options for patients with triple-negative breast cancer. **2010**, 3, 42	45
1447	Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. **2010**, 10 Suppl 2, S20-9	11
1446	DNA Repair–Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside. **2010**, 3, 29-35	5
1445	Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. **2010**, 53, 4561-84	267
1444	Mismatch repair deficient colorectal cancer in the era of personalized treatment. **2010**, 7, 197-208	165

1443	Human SIRT6 promotes DNA end resection through CtIP deacetylation. **2010**, 329, 1348-53	305
1442	Conserved structural motif for recognizing nicotinamide adenine dinucleotide in poly(ADP-ribose) polymerases and ADP-ribosylating toxins: implications for structure-based drug design. **2010**, 53, 4038-49	7
1441	Development of Poly(ADP-Ribose)Polymerase (PARP) Inhibitors in Oncology. **2010**, 45, 229-243	2
1440	The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. **2010**, 39, 8-24	631
1439	The ACF1 complex is required for DNA double-strand break repair in human cells. **2010**, 40, 976-87	162
1438	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). **2010**, 23, 71-84	51
1437	Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. **2010**, 10, 397-404	7
1436	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. **2010**, 36, 206-15	196
1435	Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. **2010**, 36, 425-35	158
1434	Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. **2010**, 36, 566-75	84
1433	Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. **2010**, 13, 29-43	54
1432	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. **2010**, 46, 9-20	95
1431	A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. **2010**, 46, 2889-95	27
1430	A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. **2010**, 394, 569-73	36
1429	53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. **2010**, 141, 243-54	1147
1428	It's diagnostics, stupid. **2010**, 141, 13-7	36
1427	Targeting homologous recombination repair defects in cancer. **2010**, 31, 372-80	81
1426	6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. **2010**, 70, 6268-76	81

1425	Microsatellite instability in colorectal cancer-the stable evidence. **2010**, 7, 153-62	522
1424	The molecular pathology of cancer. **2010**, 7, 251-65	182
1423	Triple-negative breast cancer: a clinical update. **2010**, 7, 203-211	30
1422	A decade of systems biology. **2010**, 26, 721-44	230
1421	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. **2010**, 376, 235-44	1395
1420	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. **2010**, 376, 245-51	1089
1419	PARP inhibition in BRCA-mutated breast and ovarian cancers. **2010**, 376, 211-3	38
1418	Breast pathology: beyond morphology. **2010**, 27, 91-6	14
1417	PET in women with high risk for breast or ovarian cancer. **2010**, 11, 899-905	3
1416	Triple-negative breast cancer: disease entity or title of convenience?. **2010**, 7, 683-92	588
1415	Synthetic lethal approaches to breast cancer therapy. **2010**, 7, 718-24	75
1414	The Tumor Microenvironment. **2010**,	4
1413	Exploration of synthetic lethal interactions as cancer drug targets. **2010**, 6, 1789-802	12
1412	Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. **2010**, 12, 203	32
1411	Ovarian Cancer. **2010**,	1
1410	Triple-negative breast cancer: unique biology and its management. **2010**, 28, 878-83	11
1409	Emerging therapeutics for primary peritoneal cancer. **2011**, 16, 71-84	
1408	Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ. **2011**, 2, 559	14

1407	Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. **2011**, 29, 3739-46		125
1406	Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. **2011**, 108, 1525-30		133
1405	Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. **2011**, 29, 2150-7		67
1404	Unraveling the mechanism of BRCA2 in homologous recombination. **2011**, 18, 748-54		126
1403	CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. **2011**, 71, 463-72		74
1402	Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. **2011**, 1, 29-34		39
1401	DNA repair and synthetic lethality. **2011**, 3, 176-9		21
1400	New treatment strategies in the management of breast cancer. **2011**, 9, 22-29		2
1399	Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. **2011**, 140, 1303-1313.e1-3		56
1398	Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). **2011**, 54, 5403-13		33
1397	Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. **2011**, 54, 2668-79		43
1396	Genetics and molecular biology of mesothelioma. **2011**, 189, 149-67		5
1395	Integrated genomic analyses of ovarian carcinoma. *Nature*, **2011**, 474, 609-15	50.4	5210
1394	The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. **2011**, 43, 668-72		512
1393	Preclinical Models for Anticancer Drug Development. **2011**, 89-114		1
1392	The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells. **2011**, 25, 1399-405		9
1391	Chromatin and the DNA damage response: the cancer connection. **2011**, 5, 349-67		90
1390	The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. **2011**, 5, 387-93		492

1389	Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. **2011**, 5, 368-73	141
1388	DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment. **2011**, 5, 303-7	17
1387	Molecular targeted therapy in ovarian cancer: what is on the horizon?. **2011**, 71, 947-67	12
1386	Recent developments in treatment stratification for metastatic breast cancer. **2011**, 71, 2099-113	10
1385	Role of genotyping in non-small cell lung cancer treatment: current status. **2011**, 71, 2231-46	17
1384	Personalized medicine: the road ahead. **2011**, 11, 20-6	40
1383	Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor. **2011**, 15, 831-840	29
1382	Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. **2011**, 6, 21-33	29
1381	PARP and cancer--if it's broke, don't fix it. **2011**, 364, 277-9	43
1380	Nanomedicine Approaches for Cancer Stem Cell Targeting and Personalized Cancer Treatment. **2011**, 135-144	
1379	Platinum resistance in breast and ovarian cancer cell lines. **2011**, 30, 91	85
1378	Iniparib plus chemotherapy in metastatic triple-negative breast cancer. **2011**, 364, 205-14	671
1377	Strahlenresistenzforschung. **2011**, 1	
1376	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. **2011**, 18, 1331-1335	281
1375	Breast Cancer. **2011**,	9
1374	[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. **2011**, 67 Suppl 1, S36-40	1
1373	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. **2011**, 8, 302-6	101
1372	Malignant Mesothelioma. **2011**,	1

1371	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. **2011**, 17, 875-82	204
1370	Induction Chemotherapy. **2011**,	1
1369	Poly(ADP-ribose) Polymerase. **2011**,	
1368	Emerging Therapeutic Targets in Ovarian Cancer. **2011**,	1
1367	Inherited Cancer Syndromes. **2011**,	1
1366	Molecular Determinants of Radiation Response. **2011**,	1
1365	Cancer Systems Biology, Bioinformatics and Medicine. **2011**,	3
1364	Current treatment options in triple negative breast cancer. **2010**, 32, 99-122	38
1363	Therapeutic approaches for women predisposed to breast cancer. **2011**, 62, 295-306	28
1362	p38 mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. **2011**, 13, 472-82	39
1361	Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. **2011**, 145, 529-42	782
1360	A blueprint for advancing genetics-based cancer therapy. **2011**, 147, 26-31	58
1359	Searching for synthetic lethality in cancer. **2011**, 21, 34-41	86
1358	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. **2011**, 204, 525-35	44
1357	Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. **2011**, 301, 47-56	23
1356	DNA repair systems in malignant mesothelioma. **2011**, 312, 143-9	16
1355	[Radiosensitivity, radiocurability and DNA repair]. **2011**, 15, 294-306	5
1354	PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. **2011**, 412, 379-84	15

1353	Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. **2011**, 108, 745-50	77
1352	miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. **2011**, 41, 210-20	355
1351	P53-binding protein 1: a new player for tumorigenesis and a new target for breast cancer treatment. **2011**, 77, 359-63	3
1350	A new role for miR-182 in DNA repair. **2011**, 41, 135-7	14
1349	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. **2011**, 42, 153-65	5
1348	The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. **2011**, 3, 257-67	60
1347	DNA double-strand break repair pathways, chromosomal rearrangements and cancer. **2011**, 22, 886-97	87
1346	The role of chemotherapy and targeted agents in patients with metastatic breast cancer. **2011**, 47 Suppl 3, S38-47	28
1345	The role of targeted therapy in ovarian cancer. **2011**, 47 Suppl 3, S116-30	41
1344	DNA repair as treatment target. **2011**, 47 Suppl 3, S333-5	12
1343	PARP inhibitors in cancer: moving beyond BRCA. **2011**, 12, 827-8	12
1342	Interplay and Quality Control of DNA Damage Repair Mechanisms. **2011**, 395-415	
1341	Nano delivers big: designing molecular missiles for cancer therapeutics. **2011**, 3, 34-52	40
1340	No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population. **2011**, 41, 250-7	3
1339	Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?. **2011**, 13, 218	39
1338	A protective role for BRCA2 at stalled replication forks. **2011**, 13, 314	4
1337	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. **2011**, 13, 224	302
1336	Inhibition of DNA repair as a therapeutic strategy. **2011**, 8, 23-25	

1335	Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. **2011**, 17, 854-62	46
1334	New drugs for ovarian cancer. **2011**, 22 Suppl 8, viii77-viii82	7
1333	BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. **2011**, 10, 2000-7	77
1332	PARP-3 and APLF function together to accelerate nonhomologous end-joining. **2011**, 41, 33-45	255
1331	Assessing 'radiosensitivity' with kinetic profiles of H2AX, 53BP1 and BRCA1 foci. **2011**, 101, 35-8	26
1330	The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. **2011**, 99, 331-8	76
1329	Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation. **2011**, 81, e159-64	18
1328	Pancreatic cancer. **2011**, 378, 607-20	1693
1327	AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. **2011**, 6, 299-313	6
1326	DNA Repair, Cancer and Cancer Therapy - The Current State of Art. **2011**,	1
1325	The Role of Error-Prone Alternative Non-Homologous End-Joining in Genomic Instability in Cancer. **2011**,	2
1324	Application of Host Cell Reactivation in Evaluating the Effects of Anticancer Drugs and Environmental Toxicants on Cellular DNA Repair Activity in Head and Neck Cancer. **2011**,	2
1323	Lung Cancer Metastasis. 369-381	2
1322	Drugs, Genomic Response Signatures, and Customized Cancer Therapy. 301-319	
1321	Triple-negative breast cancers: an updated review on treatment options. **2011**, 18, e173-9	54
1320	A DNA Repair Protein BRCA1 as a Potentially Molecular Target for the Anticancer Platinum Drug Cisplatin. **2011**,	
1319	. **2011**,	0
1318	Novel Therapeutic Targets in Soft Tissue Sarcomas. **2011**,	

1317	Novel treatment strategies for targeting genetic changes in endometrial cancer. 17-30	
1316	Implications of homologous recombination defectiveness in ovarian cancer. 75-82	
1315	Gynecologic Malignancies. 440-455	
1314	Human Apurinic/Apyrimidinic Endonuclease is a Novel Drug Target in Cancer. **2011**,	
1313	New Insight on Entangled DNA Repair Pathways: Stable Silenced Human Cells for Unraveling the DDR Jigsaw. **2011**,	1
1312	Emerging treatment options in the management of non-small cell lung cancer. **2011**, 2, 11-28	3
1311	The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. **2011**, 26, 352-9	26
1310	Biological and clinical significance of BRCA2. **2011**, 5, 309-316	
1309	Clinical trials in triple negative breast cancer. **2010**, 32, 123-36	24
1308	Protease addiction and synthetic lethality in cancer. **2011**, 1, 25	15
1307	Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents. **2011**, 16, 7994-8019	11
1306	[PARP inhibitors: significant progress in cancer therapy]. **2011**, 98, 277-90	0
1305	BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. **2010**, 32, 85-97	17
1304	Signal Transduction Pathways in Breast Cancer Drug Targets and Challenges. **2011**,	
1303	Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. **2011**, 6, e24148	52
1302	Functional connection between Rad51 and PML in homology-directed repair. **2011**, 6, e25814	36
1301	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. **2011**, 25, 899-904	0
1300	Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells. **2011**, 20, 508-17	12

1299	Bibliography. Lymphoma. Current world literature. **2011**, 23, 537-41	
1298	Molecular heterogeneity of triple-negative breast cancer and its clinical implications. **2011**, 23, 566-77	62
1297	PARP inhibition: opening up new horizons?. **2011**, 1, 759-762	
1296	Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. **2011**, 21, 763-70	24
1295	Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention. **2011**, 12, 1974-82	0
1294	Molecular predictors of response to therapy for breast cancer. **2011**, 17, 96-103	19
1293	Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. **2011**, 23, 526-30	16
1292	Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting. **2011**, 11, 969-73	2
1291	PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. **2011**, 11, 358-67	6
1290	Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. **2011**, 118, 6368-79	95
1289	Synthetic lethality: exploiting the addiction of cancer to DNA repair. **2011**, 117, 6074-82	144
1288	Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. **2011**, 108, 323-30	82
1287	Secondary mutations of BRCA1/2 and drug resistance. **2011**, 102, 663-9	93
1286	Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. **2011**, 102, 1882-8	17
1285	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. **2011**, 7, 197-211	11
1284	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. **2011**, 17, 304-12	77
1283	Targeting the missing links for cancer therapy. **2011**, 17, 283-4	38
1282	Strategies to improve radiotherapy with targeted drugs. **2011**, 11, 239-53	711

1281	RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. **2011**, 11, 629-43	275
1280	Cancer research: past, present and future. **2011**, 11, 749-54	119
1279	An intermittent approach for cancer chemoprevention. **2011**, 11, 879-85	51
1278	Harnessing synthetic lethal interactions in anticancer drug discovery. **2011**, 10, 351-64	204
1277	Towards systematic functional characterization of cancer genomes. **2011**, 12, 487-98	64
1276	ABC ATPase signature helices in Rad50 link nucleotide state to Mre11 interface for DNA repair. **2011**, 18, 423-31	129
1275	A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. **2011**, 18, 721-7	358
1274	Poly(ADP-ribose)-dependent regulation of Snail1 protein stability. **2011**, 30, 4365-72	47
1273	Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. *Nature*, **2011**, 471, 245-8	80.4 168
1272	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. **2011**, 104, 1356-61	6
1271	The macro domain protein family: structure, functions, and their potential therapeutic implications. **2011**, 727, 86-103	86
1270	PARP inhibitors--current status and the walk towards early breast cancer. **2011**, 20 Suppl 3, S12-9	30
1269	"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. **2011**, 38, 254-62	18
1268	Novel agents and future directions for refractory breast cancer. **2011**, 38 Suppl 2, S17-24	35
1267	Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. **2011**, 123, 196-9	10
1266	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. **2011**, 11, 7	33
1265	Structural studies of the PARP-1 BRCT domain. **2011**, 11, 37	29
1264	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. **2011**, 61, 31-49	144

1263	Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. **2011**, 61, 327-59	128
1262	Metastatic triple-negative breast cancer. **2011**, 23, 587-600	81
1261	XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. **2011**, 10, 697-713	119
1260	The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. **2011**, 10, 1003-13	31
1259	Synthetic lethality: general principles, utility and detection using genetic screens in human cells. **2011**, 585, 1-6	196
1258	Translational application of epigenetic alterations: ovarian cancer as a model. **2011**, 585, 2112-20	23
1257	Histone tails: Directing the chromatin response to DNA damage. **2011**, 585, 2883-90	26
1256	PARP inhibitors in cancer therapy: promise, progress, and puzzles. **2011**, 19, 165-7	47
1255	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. **2011**, 19, 664-78	342
1254	BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. **2011**, 20, 797-809	187
1253	Overcoming drug resistance in pancreatic cancer. **2011**, 15, 817-28	157
1252	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. **2011**, 8, 587-96	209
1251	DNA repair: from genome maintenance to biomarker and therapeutic target. **2011**, 17, 6973-84	86
1250	Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. **2011**, 16, 41-50	17
1249	Clinical management of hereditary breast cancer syndromes. **2011**, 16, 17-25	34
1248	Inherited mutations in breast cancer genes--risk and response. **2011**, 16, 3-15	52
1247	Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. **2011**, 128, 301-13	46
1246	Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. **2011**, 127, 273-81	58

1245	Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. **2011**, 129, 421-32	40
1244	Biomarkers of PARP inhibitor sensitivity. **2011**, 127, 283-6	24
1243	PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. **2011**, 127, 861-9	88
1242	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. **2011**, 130, 145-53	79
1241	Immunophenotypic predictive profiling of BRCA1-associated breast cancer. **2011**, 458, 55-64	25
1240	Overview of the development of personalized genomic medicine and surgery. **2011**, 35, 1693-9	13
1239	The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. **2011**, 67, 1007-15	10
1238	Pathology of hereditary breast cancer. **2011**, 34, 71-88	98
1237	Fanconi anaemia: from a monogenic disease to sporadic cancer. **2011**, 13, 215-21	16
1236	Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer. **2011**, 18, 120-3	10
1235	PARP Inhibitors. **2011**, 3, 44-54	6
1234	Poly(ADP-Ribose) Inhibition: Exploring a New Approach to Breast Cancer Prevention in BRCA1/2 Mutation Carriers. **2011**, 3, 165-171	1
1233	Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. **2011**, 2, 53-69	56
1232	Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery. **2011**, 54, 3-23	8
1231	Nutzen oder nicht nutzen?. **2011**, 6, 1-1	
1230	Novel approaches to treatment of leiomyosarcomas. **2011**, 13, 316-22	9
1229	PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. **2011**, 13, 442-9	36
1228	The breast cancer genome--a key for better oncology. **2011**, 11, 501	6

1227	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. **2011**, 4, 16	96
1226	On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research. **2011**, 4, 10	2
1225	Drug therapy for hereditary cancers. **2011**, 9, 5	33
1224	Effects of BRCA2 deficiency on telomere recombination in non-ALT and ALT cells. **2011**, 2, 9	6
1223	The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. **2011**, 223, 295-306	38
1222	PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. **2011**, 224, 564-74	27
1221	Functional characterization of EMSY gene amplification in human cancers. **2011**, 225, 29-42	29
1220	Systemic treatment of early breast cancer--a biological perspective. **2011**, 103, 619-26	7
1219	Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. **2011**, 3, 623-36	173
1218	High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. **2011**, 6, 424-7	70
1217	CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry. **2011**, 117, 1350-9	12
1216	How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. **2011**, 128, 251-65	66
1215	PARP inhibitor treatment in ovarian and breast cancer. **2011**, 35, 7-50	93
1214	Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. **2011**, 10, 4074-82	31
1213	The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair. **2011**, 10, 3495-504	55
1212	Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. **2011**, 7, 253-61	72
1211	RUNX1 and its understudied role in breast cancer. **2011**, 10, 3461-5	48
1210	[Synthetic lethality as a new concept for the treatment of cancer]. **2011**, 136, 1526-30	1

1209	[DNA repair pathways and non-small cell lung cancer: clinical perspectives]. **2011**, 98, 305-22	4
1208	Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. **2011**, 12, 788-96	63
1207	The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. **2011**, 12, 2034-44	29
1206	Therapeutic potential of PARP inhibitors for metastatic breast cancer. **2011**, 11, 1243-51	21
1205	BRCA mutation testing in determining breast cancer therapy. **2011**, 17, 492-9	37
1204	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. **2011**, 29, 4224-6	21
1203	Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. **2011**, 103, 334-46	211
1202	The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. **2011**, 39, 132-45	141
1201	Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. **2011**, 71, 5626-34	195
1200	Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. **2011**, 10, 670-8	17
1199	Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. **2011**, 108, 3406-11	390
1198	High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer. **2011**, 29, 4586-8; author reply 4588	17
1197	MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. **2011**, 71, 2632-42	123
1196	MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. **2011**, 286, 12157-65	55
1195	Handbook of Metastatic Breast Cancer. **2011**,	
1194	c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. **2011**, 4, ra19	70
1193	Combined hyperthermia and radiotherapy for the treatment of cancer. **2011**, 3, 3799-823	68
1192	Triple-negative breast cancer: adjuvant therapeutic options. **2011**, 2011, 696208	43

1191	Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. **2011**, 17, 401-5	74
1190	Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. **2011**, 10, 1185-93	62
1189	Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. **2011**, 10, 1949-58	140
1188	Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. **2011**, 16, 1006-20	12
1187	Development of a high-content screening method for chemicals modulating DNA damage response. **2011**, 16, 259-65	24
1186	The clinical development of inhibitors of poly(ADP-ribose) polymerase. **2011**, 22 Suppl 1, i53-9	34
1185	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. **2011**, 108, 18032-7	676
1184	kConFab: a familial breast cancer consortium facilitating research and translational oncology. **2011**, 2011, 79-81	11
1183	Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer. **2011** , 165-181	
1182	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. **2011**, 25, 199-211	118
1181	N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. **2011**, 13, 471-86	78
1180	Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. **2011**, 10, 1192-9	134
1179	Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. **2011**, 11, 959-68	23
1178	Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. **2011**, 60-69	
1177	Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. **2011**, 17, 783-91	64
1176	Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. **2011**, 108, 9851-6	250
1175	Triple-negative breast cancer: an unmet medical need. **2011**, 16 Suppl 1, 1-11	542
1174	Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. **2011**, 39, 9536-48	42

1173	DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. **2011**, 17, 2035-43	74
1172	Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. **2011**, 71, 1836-48	72
1171	The role of PARP in DNA repair and its therapeutic exploitation. **2011**, 105, 1114-22	201
1170	Germline mutations in RAD51D confer susceptibility to ovarian cancer. **2011**, 43, 879-882	379
1169	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. **2011**, 17, 1082-9	407
1168	Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. **2011**, 10, 3598-607	26
1167	BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. **2011**, 3, 66-74	74
1166	MYC, PARP1, and chemoresistance: BIN there, done that?. **2011**, 4, pe15	18
1165	Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. **2011**, 22, 1088-1093	18
1164	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. **2011**, 22, 1346-1352	140
1163	Functional viability profiles of breast cancer. **2011**, 1, 260-73	117
1162	Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. **2011**, 8, 165-71	32
1161	A review of PARP inhibitors: from bench to bedside. **2011**, 22, 268-79	154
1160	Perspectives on the History and Evolution of Tumor Models. **2011**, 3-20	4
1159	Complementary non-radioactive assays for investigation of human flap endonuclease 1 activity. **2011**, 39, e11	37
1158	A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. **2012**, 8, e1003151	25
1157	Next-generation sequencing in breast cancer: translational science and clinical integration. **2012**, 13, 637-9	10
1156	Synthetic lethality of cohesins with PARPs and replication fork mediators. **2012**, 8, e1002574	52

1155	ATM mutations in patients with hereditary pancreatic cancer. **2012**, 2, 41-6	365
1154	Genetic and Genomic Dissection of Apoptosis Signaling. **2012**, 181-197	
1153	DNA damage in Nijmegen Breakage Syndrome cells leads to PARP hyperactivation and increased oxidative stress. **2012**, 8, e1002557	23
1152	Targeting DNA base excision repair: a new strategy for personalised cancer therapy. **2012**, 12, s42-s46	0
1151	Radiobiology of Stereotactic Body Radiation Therapy/Stereotactic Ablative Radiotherapy. **2012**, 123-136	1
1150	APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. **2012**, 31, 1160-76	51
1149	A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. **2012**, 13, 14898-916	18
1148	CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. **2012**, 2012, 359041	14
1147	Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. **2012**, 30, 347-50	9
1146	BRCAness: finding the Achilles heel in ovarian cancer. **2012**, 17, 956-62	72
1145	Prevention of ER-negative breast cancer: where do we stand?. **2012**, 21, 171-81	7
1144	Targeting the DNA damage response in oncology: past, present and future perspectives. **2012**, 24, 316-24	42
1143	INT6/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells. **2012**, 72, 2006-16	14
1142	REV1 and polymerase facilitate homologous recombination repair. **2012**, 40, 682-91	117
1141	Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. **2012**, 16 Suppl 2, S83-9	6
1140	Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. **2012**, 307, 408-10	9
1139	Triple-negative breast cancer: are we making headway at least?. **2012**, 4, 195-210	60
1138	Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. **2012**, 82, 322-32	30

1137	Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. **2012**, 19, 3922-36	36
1136	Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy. **2012**, 12, 788-803	4
1135	[PARP inhibitors and breast cancer: update and perspectives]. **2012**, 99, 441-51	2
1134	Integrating breast cancer genetics into clinical practice. **2012**, 8, 99-112	4
1133	Selective tumor killing based on specific DNA-damage response deficiencies. **2012**, 13, 239-46	9
1132	Targeted therapy for brain tumours: role of PARP inhibitors. **2012**, 12, 218-36	16
1131	DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. **2012**, 12, 356-71	25
1130	Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. **2012**, 12, 329-38	7
1129	Inhibiting homologous recombination for cancer therapy. **2012**, 13, 61-8	49
1128	Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. **2012**, 13, 1523-35	50
1127	Oxidized base damage and single-strand break repair in mammalian genomes: role of disordered regions and posttranslational modifications in early enzymes. **2012**, 110, 123-53	55
1126	Evolutionary pathways in BRCA1-associated breast tumors. **2012**, 2, 503-11	95
1125	Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. **2012**, 11, 990-7	64
1124	Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. **2012**, 12, 672-7	10
1123	Twenty Years of G-CSF. **2012**,	6
1122	New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. **2012**, 28, 582-6	11
1121	Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. **2012**, 107, 1776-82	384
1120	DNA Double-Strand Break Repair by Non-homologous End Joining and Its Clinical Relevance. **2012**, 161-189	2

1119	The Role of PARP in DNA Repair and its Therapeutic Exploitation. **2012**, 55-73	
1118	Mission therapeutics. **2012**, 30, 206	1
1117	PARP target practice. **2012**, 5, 323-323	4
1116	Nef-arious goings-on at the Golgi. **2012**, 19, 661-2	2
1115	LEDGF (p75) promotes DNA-end resection and homologous recombination. **2012**, 19, 803-10	130
1114	Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation. **2012**, 107, 1317-26	11
1113	Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. **2012**, 106, 468-74	103
1112	Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. **2012**, 11, 1948-58	54
1111	Advances in Ovarian Cancer Management. **2012**,	1
1110	A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. **2012**, 335, 348-53	315
1109	Pancreatic cancer and premalignant tumors. **2012**, 123-134.e3	
1108	Targeting abnormal DNA repair in therapy-resistant breast cancers. **2012**, 10, 96-107	62
1107	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. **2012**, 30, 1996-2004	167
1106	Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. **2012**, 2012, 829315	10
1105	Combination drug delivery approaches in metastatic breast cancer. **2012**, 2012, 915375	89
1104	A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. **2012**, 18, 1726-34	160
1103	Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy. **2012**, 2, 635-49	13
1102	Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. **2012**, 2, 186	67

1101	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. **2012**, 287, 22408-17	62
1100	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. **2012**, 18, 1655-62	182
1099	Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. **2012**, 109, 6590-5	34
1098	Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. **2012**, 24, 564-71	40
1097	Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. **2012**, 18, 510-23	146
1096	Studying synthetic lethal interactions in the zebrafish system: insight into disease genes and mechanisms. **2012**, 5, 33-7	5
1095	Role of PARP inhibitors in cancer biology and therapy. **2012**, 19, 3907-21	94
1094	Synthetic lethality and PARP-inhibitors in oral and head & neck cancer. **2012**, 18, 5431-41	6
1093	The role of PARP inhibitors in the treatment of ovarian carcinomas. **2012**, 18, 3770-4	13
1092	Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials. **2012**, 8, 104-110	
1091	Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box". **2012**, 18, 665-73	6
1090	Bibliography. Head and neck. Current world literature. **2012**, 24, 345-9	
1089	Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer. **2012**, 4, 1209-1212	1
1088	Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2. **2011**, 13, 44-51	32
1087	Poly(ADP-ribose) polymerase inhibitors and epithelial ovarian cancer. **2012**, 156-170	
1086	PARP inhibitors in lung cancer. **2012**, 7, S392-3	7
1085	DNA repair dysregulation from cancer driver to therapeutic target. **2012**, 12, 801-17	680
1084	Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. **2012**, 11, 923-36	196

1083	Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response. **2012**, 167, 141-50		7
1082	Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. **2012**, 30, 283-8		363
1081	BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies. **2012**, 11, 687-94		19
1080	The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. **2012**, 19, 685-692		157
1079	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. **2012**, 52, 549-73		82
1078	Glioblastoma multiforme: overview of current treatment and future perspectives. **2012**, 26, 825-53		105
1077	Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. **2012**, 39, 517-31		13
1076	A multiplexed siRNA screening strategy to identify genes in the PARP pathway. **2012**, 17, 1316-28		4
1075	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. **2012**, 18, 5806-15		118
1074	The role of BRCA1 and BRCA2 in prostate cancer. **2012**, 14, 409-14		85
1073	Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1-depleted cancers. **2012**, 72, 5934-44		28
1072	Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. **2012**, 160, 178-97		26
1071	PARPs and the DNA damage response. **2012**, 33, 1433-40		95
1070	Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. **2012**, 72, 5547-55		19
1069	Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. **2012**, 72, 5675-82		77
1068	Cancers du sein triples n□atifs: Une revue de la litt□ature. **2012**, 571-588		
1067	Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. **2012**, 72, 2802-13		58
1066	The DNA damage response and cancer therapy. *Nature*, **2012**, 481, 287-94	50.4	1118

1065	Genetic heterogeneity and cancer drug resistance. **2012**, 13, e178-85		321
1064	DNA damage: placing BRCA1 in the proper context. **2012**, 22, R806-8		6
1063	Integrating the NCI-60 Data with 'Omics' for Drug Discovery. **2012**, 73, 420-429		2
1062	Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. **2012**, 135, 505-17		54
1061	Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. **2012**, 17, 205-16		61
1060	Cancer vulnerabilities unveiled by genomic loss. **2012**, 150, 842-54		163
1059	Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. **2012**, 83, e677-83		27
1058	The pioneering spirit of Takashi Sugimura: his studies of the biochemistry of poly(ADP-ribosylation) and of cancer. **2012**, 151, 221-8		1
1057	Biologic therapies and personalized medicine in gynecologic malignancies. **2012**, 39, 131-44		1
1056	Homologous recombination and its regulation. **2012**, 40, 5795-818		418
1055	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. **2012**, 72, 5588-99		1186
1054	The evolution of personalized cancer genetic counseling in the era of personalized medicine. **2012**, 11, 539-44		20
1053	PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. **2012**, 72, 1608-13		203
1052	Molecular oncology: The positive in the negative. *Nature*, **2012**, 485, S52-3	50.4	4
1051	Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. **2012**, 51, 6246-59		30
1050	A snapshot of chemoresistance to PARP inhibitors. **2012**, 33, 42-8		32
1049	Deregulated MYC expression induces dependence upon AMPK-related kinase 5. *Nature*, **2012**, 483, 608-12	50.4	198
1048	New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. **2012**, 13, 411-24		811

1047	Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. **2012**, 287, 4198-210	74
1046	Molecular-targeted therapies for ovarian cancer: prospects for the future. **2012**, 17, 424-9	25
1045	Mechanisms of BRCA1 tumor suppression. **2012**, 2, 679-84	95
1044	Essential gene profiles in breast, pancreatic, and ovarian cancer cells. **2012**, 2, 172-189	221
1043	Systemic therapy options in BRCA mutation-associated breast cancer. **2012**, 135, 355-66	45
1042	On using functional genetics to understand breast cancer biology. **2012**, 4, a013516	1
1041	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. **2012**, 12, 635-42	88
1040	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. **2012**, 2, 1036-47	418
1039	HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. **2012**, 72, 4796-806	45
1038	Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. **2012**, 45, 371-83	123
1037	BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. **2012**, 46, 125-35	212
1036	Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. **2012**, 36, 190-7	21
1035	Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. **2012**, 319, 232-241	45
1034	[Double strand break repair, one mechanism can hide another: alternative non-homologous end joining]. **2012**, 16, 1-10	7
1033	Defective homologous recombination in human cancers. **2012**, 38, 89-100	54
1032	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. **2012**, 38, 303-10	24
1031	Drug resistance in the mouse cancer clinic. **2012**, 15, 81-9	27
1030	Collateral sensitivity as a strategy against cancer multidrug resistance. **2012**, 15, 98-105	215

1029	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. **2012**, 22, 45-9	36
1028	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. **2012**, 22, 21-7	22
1027	The right time, the right place: will targeting human cancer-associated mutations to the mouse provide the perfect preclinical model?. **2012**, 22, 28-35	5
1026	Dissecting the heterogeneity of triple-negative breast cancer. **2012**, 30, 1879-87	304
1025	Evolution of the cancer genome. **2012**, 13, 795-806	424
1024	Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. **2012**, 18, 6400-6	82
1023	Lupus antibody tops cancer cells. **2012**, 4, 157fs38	
1022	Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. **2012**, 4, 1087-96	85
1021	Comprehensive predictions of target proteins based on protein-chemical interaction using virtual screening and experimental verifications. **2012**, 12, 2	7
1020	Pathway choice in DNA double strand break repair: observations of a balancing act. **2012**, 3, 9	153
1019	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. **2012**, 12, 587-98	415
1018	Overcoming implementation challenges of personalized cancer therapy. **2012**, 9, 542-8	96
1017	Homologous recombination in eukaryotes. **2012**, 110, 155-206	24
1016	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. **2012**, 9, 144-55	79
1015	Cancer treatment according to BRCA1 and BRCA2 mutations. **2012**, 9, 520-8	56
1014	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. **2012**, 23, 1156-1164	115
1013	PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. **2012**, 72, 1579-90	25
1012	Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. **2012**, 2, 1048-63	335

1011	Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. **2012**, 4, 51-72	12
1010	Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. **2012**, 11, 3837-50	125
1009	Functional drug-gene interactions in lung cancer. **2012**, 12, 291-302	5
1008	Targeting the subtypes of breast cancer: rethinking investigational drugs. **2012**, 21, 191-204	1
1007	PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. **2012**, 84, 1318-31	18
1006	Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. **2012**, 9, e51-e58	13
1005	Links between genome integrity and BRCA1 tumor suppression. **2012**, 37, 418-24	84
1004	Omics and therapy - a basis for precision medicine. **2012**, 6, 128-39	30
1003	The secret life of Bcl-2: apoptosis-independent inhibition of DNA repair by Bcl-2 family members. **2012**, 751, 247-257	51
1002	Practical perspectives of personalized healthcare in oncology. **2012**, 29, 656-64	8
1001	Predictive markers in early research and companion diagnostic developments in oncology. **2012**, 29, 651-5	6
1000	Management of women with BRCA1/2 mutation-associated breast cancer. **2012**, 1, 157-164	
999	LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy. **2012**, 8, 1643-56	91
998	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. **2012**, 366, 1382-92	1265
997	Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. **2012**, 28, 509-17	74
996	BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer. **2012**, 8, 982-93	24
995	Hereditary gynecologic cancers: risk assessment, counseling, testing and management. **2012**, 39, 165-81	8
994	Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. **2012**, 110, 289-314	34

993	Emerging new agents for the management of patients with non-small cell lung cancer. **2012**, 72 Suppl 1, 37-52	17
992	Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. **2012**, 26, 649-70, ix	20
991	BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. **2012**, 31, 3667-78	62
990	A magnetic bead-integrated chip for the large scale manufacture of normalized esiRNAs. **2012**, 7, e39419	1
989	Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. **2012**, 7, e39588	51
988	A brief review on the biological effects of radiation on cells. **2012**, 59, 89-97	1
987	Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. **2012** , 7, e52079	10
986	Defective cell cycle checkpoints as targets for anti-cancer therapies. **2012**, 3, 9	45
985	Major clinical research advances in gynecologic cancer in 2011. **2012**, 23, 53-64	29
984	Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. **2012**, 2012, 703858	12
983	Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. **2012**, 18, 2745-55	52
982	Evolving drug targets in DNA base excision repair for cancer therapy. **2012**, 5, 1-2	1
981	The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. **2012**, 226, 703-12	48
980	On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. **2012**, 26, 417-32	490
979	Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. **2012**, 55, 3101-12	74
978	Tracking evolution of BRCA1-associated breast cancer. **2012**, 2, 486-8	2
977	MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. **2012**, 72, 4037-46	98
976	Molecular mechanisms of cisplatin resistance. **2012**, 31, 1869-83	1567

975	DNA methylation biomarkers in cancer: progress towards clinical implementation. **2012**, 12, 473-87	126
974	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. **2012**, 30, 2654-63	810
973	Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. **2012**, 4, 1093-111	19
972	BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. **2012**, 227, 200-8	25
971	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. **2012**, 4, 515-27	103
970	Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. **2012**, 55, 1840-51	31
969	Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. **2012**, 30, 175-9	15
968	Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. **2012**, 131, 2433-44	67
967	Targeted therapy for triple-negative breast cancer: where are we?. **2012**, 131, 2471-7	63
966	Personalized medicine: hope or hype?. **2012**, 33, 1564-70	51
965	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. **2012**, 30, 372-9	381
964	Inhibition of homologous recombination by the PCNA-interacting protein PARI. **2012**, 45, 75-86	161
963	Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. **2012**, 118, 3703-9	61
962	BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. **2012**, 31, 131-42	9
961	Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. **2012**, 72, 2814-21	227
960	Unveiling combinatorial regulation through the combination of ChIP information and in silico cis-regulatory module detection. **2012**, 40, e90	17
959	The role of PARP1 in the DNA damage response and its application in tumor therapy. **2012**, 6, 156-64	56
958	PARP pairs up to PARsylate. **2012**, 19, 660-1	4

957	Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. **2012**, 134, 511-7	30
956	Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. **2012**, 134, 649-59	75
955	Targeting DNA repair and the cell cycle in glioblastoma. **2012**, 107, 463-77	28
954	Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. **2012**, 69, 923-30	9
953	Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. **2012**, 460, 237-49	341
952	Inhibiteurs de PARP et radiothérapie. **2012**, 14, 267-270	
951	Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-**2012**, 17, 691-701	5
950	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. **2012**, 133, 865-80	87
949	Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. **2012**, 64, 605-13	76
948	The paradox of triple negative breast cancer: novel approaches to treatment. **2012**, 18, 41-51	52
947	Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). **2012**, 61, 329-39	15
946	Balancing repair and tolerance of DNA damage caused by alkylating agents. **2012**, 12, 104-20	585
945	Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. **2012**, 586, 1984-92	49
944	Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. **2012**, 11, 522-4	13
943	RECQ1 plays a distinct role in cellular response to oxidative DNA damage. **2012**, 11, 537-49	43
942	Stratified medicine for cancer therapy. **2012**, 17, 261-8	5
941	Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors. **2012**, 50, 264-73	27
940	Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. **2012**, 83, 741-6	21

939	The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. **2012**, 84, 137-46	364
938	Predicting recurrence after radiotherapy in head and neck cancer. **2012**, 22, 108-18	54
937	The endoperoxide ascaridol shows strong differential cytotoxicity in nucleotide excision repair-deficient cells. **2012**, 259, 302-10	18
936	Oncolytic viruses: a new paradigm for treatment of head and neck cancer. **2012**, 113, 155-60	5
935	Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. **2012**, 133, 334-50	77
934	Hereditary ovarian cancer: beyond the usual suspects. **2012**, 124, 347-53	107
933	A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. **2012**, 103, 504-9	53
932	Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation. **2012**, 103, 1045-50	47
931	Familial breast cancer. **2012**, 82, 105-14	122
930	Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. **2012**, 109, 713-9	31
929	Advances in using PARP inhibitors to treat cancer. **2012**, 10, 25	103
928	Uncoupling of RAD51 focus formation and cell survival after replication fork stalling in RAD51D null CHO cells. **2012**, 53, 114-24	9
927	Insights into the targeted elimination of BRCA1-defective cancer stem cells. **2012**, 32, 948-67	4
926	Treatment of Metastatic Triple-Negative Breast Cancer. **2012**, 4, 10-21	
925	The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation. **2012**, 69, 951-62	19
924	Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. **2012**, 131, 809-18	23
923	The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. **2012**, 131, 333-40	13
922	Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer. **2012**, 132, 335-40	9

921	Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures. **2012**, 138, 95-102	5
920	Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. **2013**, 107, 15-22	170
919	Structure activity relationship of plumbagin in BRCA1 related cancer cells. **2013**, 52, 392-403	20
918	The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. **2013**, 3, 11	29
917	The role and clinical significance of DNA damage response and repair pathways in primary brain tumors. **2013**, 3, 10	11
916	Systems Biology of Apoptosis. **2013**,	2
915	Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. **2013**, 139, 392-404	89
914	Prostate Cancer. **2013**,	5
913	Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. **2013**, 23, 4501-5	21
912	Management of Microbial Resources in the Environment. **2013**,	5
911	A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. **2013**, 49, 2972-8	135
910	DNA helicases involved in DNA repair and their roles in cancer. **2013**, 13, 542-58	223
909	Genomic instability in multiple myeloma: mechanisms and therapeutic implications. **2013**, 13 Suppl 1, S69-82	28
908	The Role of Platinum Compounds for the Treatment of Breast Cancer. **2013**, 5, 11-22	1
907	Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. **2013**, 13, 90	16
906	Deubiquitylating enzymes and DNA damage response pathways. **2013**, 67, 25-43	71
905	PARP inhibitors: polypharmacology versus selective inhibition. **2013**, 280, 3563-75	61
904	Advances in DNA Repair in Cancer Therapy. **2013**,	

903	RAD51 Is a Key Protein of DNA Repair and Homologous Recombination in Humans. **2013**, 281-302	1
902	Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. **2013**, 10, 981-4	222
901	Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. **2013**, 4, 1701	31
900	Identification of miRNA modulators to PARP inhibitor response. **2013**, 12, 394-402	52
899	MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. **2013**, 72, 117-25	12
898	PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. **2013**, 12, 529-34	40
897	Synthesis of Olaparib derivatives and their antitumor activities. **2013**, 29, 231-235	3
896	RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. **2013**, 49, 858-71	433
895	BRCA1 and CtIP suppress long-tract gene conversion between sister chromatids. **2013**, 4, 2404	39
894	The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. **2013**, 138, 783-94	58
893	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. **2013**, 32, 5377-87	71
892	Management of Gynecological Cancers in Older Women. **2013**,	1
891	Recessive cancer genes engage in negative genetic interactions with their functional paralogs. **2013**, 5, 1519-26	14
890	Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. **2013**, 161, 156-64	17
889	BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. **2013**, 7, 567-79	100
888	H2AX a promising biomarker for lung cancer: a review. **2013**, 31, 582-99	27
887	Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. **2013**, 128, 483-7	23
886	Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. **2013**, 34, 2486-97	47

885	Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. **2013**, 25, 578-85	339
884	Multiple Sclerosis Immunology. **2013**,	4
883	Poly(ADP-ribosyl)ation in carcinogenesis. **2013**, 34, 1202-16	39
882	Molecular pathways: PI3K pathway targets in triple-negative breast cancers. **2013**, 19, 3738-44	49
881	Cancer genome landscapes. **2013**, 339, 1546-58	5058
880	Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. **2013**, 12, 1002-15	80
879	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. **2013**, 110, 17041-6	170
878	Breast and Gynecological Cancers. **2013**,	5
877	Appraising iniparib, the PARP inhibitor that never was--what must we learn?. **2013**, 10, 688-96	66
876	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. **2013**, 19, 5485-93	103
875	Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. **2013**, 22, 561-8	24
874	Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. **2013**, 5, 189ra78	72
873	Prostate Cancer: Shifting from Morphology to Biology. **2013**,	1
872	siRNA delivery for the treatment of ovarian cancer. **2013**, 63, 95-100	16
871	BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. **2013**, 24 Suppl 8, viii22-viii27	31
870	miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. **2013**, 105, 1750-8	123
869	Structure-based DNA-targeting strategies with small molecule ligands for drug discovery. **2013**, 33, 1119-73	63
868	Mechanisms of resistance to therapies targeting BRCA-mutant cancers. **2013**, 19, 1381-8	300

867	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. **2013**, 15, R88	139
866	Mouse models of BRCA1 and their application to breast cancer research. **2013**, 32, 25-37	44
865	PARP inhibitors: current status and implications for anticancer therapeutics. **2013**, 8, 46	3
864	ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. **2013**, 32, 95	68
863	Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. **2013**, 15, R108	54
862	BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. **2013**, 13, 523	39
861	DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. **2013**, 14, 689-700	18
860	Chromatin structure in double strand break repair. **2013**, 12, 800-10	43
859	Epigenetic modifications in breast cancer and their role in personalized medicine. **2013**, 183, 1052-1063	58
858	Identification of novel PARP-1 inhibitors by structure-based virtual screening. **2013**, 23, 5790-4	17
857	Cancer drug resistance: an evolving paradigm. **2013**, 13, 714-26	2864
856	A review of iniparib in ovarian cancer. **2013**, 22, 399-405	3
855	The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. **2013**, 31, 461-8	44
854	Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. **2013**, 104, 1593-9	20
853	Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. **2013**, 12, 2135-44	19
852	Pancreatic cancer genomics: insights and opportunities for clinical translation. **2013**, 5, 26	18
851	Current and future directions for Phase II trials in high-grade glioma. **2013**, 13, 369-87	4
850	ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. **2013**, 4, 2697	30

849	Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. **2013**, 31, 46-58	19
848	Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. **2013**, 12, 104-16	170
847	MicroRNAs and DNA damage response: implications for cancer therapy. **2013**, 12, 32-42	79
846	Molecular pathways: targeting PARP in cancer treatment. **2013**, 19, 977-84	63
845	DNA double strand break repair: a radiation perspective. **2013**, 18, 2458-72	57
844	New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. **2013**, 19, 961-8	238
843	Oxidative stress and the DNA mismatch repair pathway. **2013**, 18, 2420-8	40
842	Toward personalized cancer nanomedicine - past, present, and future. **2013**, 5, 48-65	34
841	DNA damage response in peritumoral regions of oesophageal cancer microenvironment. **2013**, 34, 139-45	13
840	Targeting DNA repair mechanisms in cancer. **2013**, 137, 298-308	91
839	Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. **2013**, 121, 54-63	126
838	Lack of expression of the proteins GMPR2 and PPARre associated with the basal phenotype and patient outcome in breast cancer. **2013**, 137, 127-37	15
837	Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. **2013**, 114, 514-24	46
836	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. **2013**, 229, 422-9	235
835	Targeted therapy for breast cancer. **2013**, 183, 1096-1112	83
834	Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. **2013**, 340, 227-33	16
833	Human inositol polyphosphate multikinase regulates transcript-selective nuclear mRNA export to preserve genome integrity. **2013**, 51, 737-50	58
832	PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. **2013**, 80, 216-22	36

831	Unraveling DNA damage response-signaling networks through systems approaches. **2013**, 87, 1635-48	15
830	Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. **2013**, 24, 751-65	366
829	53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes. **2013**, 128, 493-9	24
828	New paradigms and future challenges in radiation oncology: an update of biological targets and technology. **2013**, 5, 173sr2	151
827	Regulation of DNA damage responses by ubiquitin and SUMO. **2013**, 49, 795-807	447
826	Synthetic Lethal Genetic Interaction Networks and Their Utility for Anticancer Therapy. **2013**, 413-428	
825	Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. **2013**, 20, 317-25	347
824	Genetic Networks. **2013**, 115-135	1
823	Nonfamilial breast cancer subtypes. **2013**, 973, 279-95	5
822	Revisiting ovarian cancer preclinical models: implications for a better management of the disease. **2013**, 39, 561-8	21
821	Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. **2013**, 63, 920-6	313
820	Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. **2013**, 39, 403-12	30
819	Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. **2013**, 56, 2885-903	62
818	Ovarian cancer: in search of better marker systems based on DNA repair defects. **2013**, 14, 640-73	17
817	RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. **2013**, 133, 275-85	27
816	BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. **2013**, 200, 187-202	61
815	Role of 53BP1 oligomerization in regulating double-strand break repair. **2013**, 110, 2146-51	53
814	Macro domains as metabolite sensors on chromatin. **2013**, 70, 1509-24	39

813	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. **2013**, 34, 1217-56	265
812	Ovarian Cancer. **2013**, 714-721	1
811	PARP-1 and gene regulation: progress and puzzles. **2013**, 34, 1109-23	183
810	Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. **2013**, 10, 427-31	94
809	PARP inhibitors in cancer therapy: an update. **2013**, 23, 503-14	40
808	PARP inhibition as a prototype for synthetic lethal screens. **2013**, 986, 123-37	3
807	Synthetic lethality and cancer: cohesin and PARP at the replication fork. **2013**, 29, 290-7	26
806	Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death. **2013**, 18, 963-79	11
805	Emerging therapies for triple-negative breast cancer. **2013**, 2, 47-55	0
804	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. **2013**, 32, 479-92	38
803	Touching base with PARPs: moonlighting in the repair of UV lesions and double-strand breaks. **2013** , 38, 321-30	44
802	Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. **2013**, 23, 693-704	216
801	Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. **2013**, 169, 1745-65	53
800	ETS Fusion Genes in Prostate Cancer. **2013**, 139-183	4
799	Enhancing radiation therapy for patients with glioblastoma. **2013**, 13, 569-81	10
798	The recognition and removal of cellular poly(ADP-ribose) signals. **2013**, 280, 3491-507	87
797	Latest research and treatment of advanced-stage epithelial ovarian cancer. **2013**, 10, 211-24	365
796	Epigenetic profiling joins personalized cancer medicine. **2013**, 13, 473-9	30

795	G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. **2013**, 135, 9640-3	101
794	Genetic interaction networks: toward an understanding of heritability. **2013**, 14, 111-33	81
793	Strategies for optimizing the response of cancer and normal tissues to radiation. **2013**, 12, 526-42	255
792	Cell Death Signaling in Cancer Biology and Treatment. **2013**,	1
791	53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. **2013**, 153, 1266-80	247
790	Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. **2013**, 3, 68-81	346
789	Replicating damaged DNA in eukaryotes. **2013**, 5, a019836	10
788	FBH1 helicase disrupts RAD51 filaments in vitro and modulates homologous recombination in mammalian cells. **2013**, 288, 34168-34180	52
787	DNA Damage Repair Pathways and Synthetic Lethality. **2013**, 183-210	
786	Homologous Recombination in Mammals. **2013**, 91-120	1
785	RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. **2013**, 32, 3552-8	132
784	Emerging Roles of SIRT1 in Cancer Drug Resistance. **2013**, 4, 82-90	56
783	Loss of TRPM2 function protects against irradiation-induced salivary gland dysfunction. **2013**, 4, 1515	45
782	Targeting an Achilles' heel of cancer with a WRN helicase inhibitor. **2013**, 12, 3329-35	42
781	Targeted approaches to triple-negative breast cancer: current practice and future directions. **2013**, 20, 605-12	15
780	Genetic and Genomic Factors in Breast Cancer. **2013**, 29-47	
779	Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose). **2013**, 126, 4414-23	45
778	Current status and evolution of preclinical drug development models of epithelial ovarian cancer. **2013**, 3, 296	29

777	PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. **2013**, 9, e1003531	89
776	Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity. **2013**, 3, 257	26
775	PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. **2013**, 3, 279	19
774	New developments in the treatment of ovarian cancer--future perspectives. **2013**, 24 Suppl 10, x69-x76	32
773	Hereditary breast cancer: the era of new susceptibility genes. **2013**, 2013, 747318	172
772	New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. **2013**, 2013, 852839	20
771	Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. **2013**, 3, 290	142
770	The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. **2013**, 3, 237	45
769	DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. **2013**, 3, 113	167
768	Molecular Insights into Poly(ADP-ribose) Recognition and Processing. **2012**, 3, 1-17	29
767	Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps. **2013**, 9, e1003016	19
766	Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1. **2013**, 9, e1003413	40
765	An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. **2013**, 9, e1003254	70
764	A high-throughput functional complementation assay for classification of BRCA1 missense variants. **2013**, 3, 1142-55	92
763	ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. **2013**, 73, 3683-91	137
762	ZNF365 promotes stalled replication forks recovery to maintain genome stability. **2013**, 12, 2817-28	13
761	Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice. **2013**, 25, 609-14	18
760	EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. **2013**, 73, 6254-63	31

759	Inhibition of DNA damage repair by artificial activation of PARP with siDNA. **2013**, 41, 7344-55	27
758	PARI overexpression promotes genomic instability and pancreatic tumorigenesis. **2013**, 73, 2529-39	25
757	Added value of family history in counseling about risk of BRCA1/2 mutation in early-onset epithelial ovarian cancer. **2013**, 23, 1406-10	3
756	Personalized medicine for metastatic breast cancer. **2013**, 25, 615-24	4
755	Nonhomologous end-joining promotes resistance to DNA damage in the absence of an ADP-ribosyltransferase that signals DNA single strand breaks. **2013**, 126, 3452-61	11
754	Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. **2013**, 33, 3309-20	62
753	Cisplatin resistance associated with PARP hyperactivation. **2013**, 73, 2271-80	123
752	Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.	
751	Simulation of cancer cell line pharmacogenomics data to optimise experimental design and analysis strategy.	
750	A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistance.	
749	Universal Panel Testing of Pancreatic Cancer Cases for Cancer Predisposition.	
748	MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?.	1
747	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.	
746	Detection of functional protein domains by unbiased genome-wide forward genetic screening.	
745	DNA Damage Repair. **2018**, 405-417	
744	Rev7 and 53BP1/Crb2 prevent RecQ helicase-dependent hyper-resection of DNA double-strand breaks.	
743	Molecular Life Sciences. **2018**, 526-527	
742	Hereditary breast and ovarian cancer genetics: Genetic testing in Serbia. **2018**, 115-140	

741	A chemoproteomic portrait of the oncometabolite fumarate.	
740	Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.	
739	Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. **2018**, 10, e2685	2
738	Subjugation of TGF Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End-Joining.	
737	PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress.	
736	Design, Synthesis and Evaluation of the Biological Activities of Some New Carbohydrazide and Urea Derivatives. **2018**, 15, 304-308	0
735	Targeting Wnt Signaling To Overcome PARP Inhibitor Resistance.	2
734	Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens.	2
733	Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients. **2018**, 20, 19-25	
732	Characterisation of deubiquitylating enzymes in the cellular response to high-LET ionising radiation and complex DNA damage.	
731	Novel Poly (ADP-Ribose) Polymerase Inhibitor AZD2461 Combined with Valproic Acid Exerts Mild Antagonistic Effects in Hela Cells. **2018**, In Press,	
730	Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer.	0
729	A Pedigree of Familial Breast Cancer with Seven Breast Cancer Patients in Four Generations. **2019**, 80, 848-853	
728	Unmet Needs and Future Outlook of Mesothelioma Management. **2019**, 331-340	
727	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. **2019**, 613-631	
726	Adjuvant Systemic Chemotherapy for HER2-Negative Disease. **2019**, 129-171	
725	Epidemiology, Risk Factors, and Prevention. **2019**, 39-61	
724	Breast Cancer Receptors and Targeting Strategies. **2019**, 79-108	0

723 Genetic Counseling. **2019**, 399-412

722 Maintenance Treatment for Recurrent Ovarian Carcinoma Evidence Supporting the Efficacy and Safety of PARP Inhibitors. **2019**, 15, 29 0

721 Quick glance at Fanconi anemia and BRCA2/FANCD1. **2019**, 6, 326-336

720 Application of Biomarkers for Common Cancers in Molecular Diagnosis. **2019**, 09, 17-23

719 What is the Current Effectiveness of Olaparib for Breast Cancer Patients with a BRCA Mutation? A Systematic Review. **2019**, 13, 39-59

718 The oncoprotein DEK affects the outcome of PARP1/2 inhibition during replication stress.

717 Integration of pathway, cellular and genetic context reveals principles of synthetic lethality that affect reproducibility.

716 Germline genomic patterns are associated with cancer risk, oncogenic pathways and clinical outcomes. 1

715 Higher prevalence of homologous recombination-deficiency in lung squamous carcinoma from African Americans.

714 Genetic screens in isogenic mammalian cell lines without single cell cloning. 0

713 Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signatures.

712 Drug Combination Antagonism and Single Agent Dominance Result from Differences in Death Activation Kinetics. 0

711 Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair. **2019**, 42, 2426-2434 3

710 Neurological Complications of Targeted Therapies. **2020**, 341-363

709 A 53BP1 Inhibitory Compound Enhances CRISPR Efficiency for Generating Knock-In Mice.

708 Role of Precision Medicine in Patients with CNS Metastasis. **2020**, 69-82

707 Olaparib, a new hope for ovarian cancer. **2020**, 57, 346-347

706 ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in patients with metastatic urothelial cancer.

705	The Molecular Landscape of Asian Breast Cancers Reveals Clinically Relevant Population-Specific Differences.	0
704	WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.	
703	Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51.	
702	Precision combination therapies based on recurrent oncogenic co-alterations.	
701	Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer Cells.	
700	PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.	
699	Molecular Context of ADP-ribosylation in Schistosomes for Drug Discovery and Vaccine Development. **2021**, 18, 473-484	
698	Homologous recombination defects in Shwachman-Diamond syndrome and Diamond-Blackfan anemia.	1
697	The Precision Oncology Program for Cancer of the Prostate (POPCaP) Network: A Veterans Affairs/Prostate Cancer Foundation Collaboration. **2020**, 37, S48-S53	
696	Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition.	
695	Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. **2021**, 11, 742139	0
694	PARP5B is required for nonhomologous end joining during tumorigenesis in vivo. **2022**, 61, 85-98	2
693	PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later. **2021**, 32, 1460-1462	1
692	Aberrant transcript usage is associated with homologous recombination deficiency and predicts therapeutic response. **2021**,	0
691	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. **2021**, 11, 718871	1
690	A mixture model for signature discovery from sparse mutation data. **2021**, 13, 173	6
689	Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer.	
688	Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy.	1

687 Therapeutic vulnerability to PARP1/2 inhibition in RB1-mutant osteosarcoma.

686 ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination deficient cells.

685 Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk. **2020**, 55-68

684 Targeting the Key Signaling Pathways in Breast Cancer Treatment Using Natural Agents. **2020**, 137-183 2

683 High-Throughput Functional Evaluation of BRCA2 Variants of Unknown Significance.

682 A Mixture Model for Signature Discovery from Sparse Mutation Data. **2020**, 271-272 0

681 Two Cases of HER2-negative Recurrent Breast Cancer Treated with Olaparib as a Second and Third Line of Therapy with Good Responses. **2020**, 81, 1497-1501

680 Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. **2020**, 41, 9-14

679 Rare mutations in breast cancer and implications in the clinic: Oscillation between sharp horns of dilemmas!. **2020**, 3, 302

678 Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer. **2020**, 1, 26-52

677 Chromatin-Bound PARP1 Correlates with Upregulation of Inflammatory Genes in Response to Long-Term Treatment with Veliparib.

676 ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738.

675 Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report. **2020**, 11, 243-249 0

674 Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report. **2020**, 12, 243-249

673 Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in replication fork stability controlled by ATR.

672 Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. **2021**, 4, 1270 1

671 Discovery of Quinazoline-2,4(1,3)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors-Design, Synthesis, Antitumor Activity, and X-ray Crystal Structure Analysis. **2021**, 64, 16711-16730 2

670 Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. **2021**, 3

669	Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. **2021**, 163, 563-568	1
668	Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.	
667	Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes. **2021**, 13, 174	1
666	Poly(ADP-ribose)-binding and macroH2A mediate recruitment and functions of KDM5A at DNA lesions.	
665	A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death.	
664	A meta-analysis of clinical cases of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.	
663	PARG inhibition induces replication catastrophe in ovarian cancer cells with down-regulated DNA replication genes.	
662	CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors.	
661	In Situ Analysis of DNA Repair Processes of Tumor Suppressor BRCA1. **2009**, 2211-2214	
660	Recombinational DNA Repair in Eukaryotes. 592-603	
659	The contribution of PARP1, PARP2 and poly(ADP-ribosyl)ation to base excision repair in the nucleosomal context.	
658	Wide-spectrum cancer killing by ENDOD1 ablation.	
657	CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependencies.	
656	Single-molecule measurements reveal that PARP1 condenses DNA by loop formation.	
655	The Treatment of Clear Cell Ovarian Cancer with the Poly(ADP- Ribose) Polymerase (PARP1) Inhibitors (AG14361,Veliparib,Olaparib) as Chemosensitizers.	
654	Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. **2008**, 1, 343-51	17
653	The molecular genetics of breast cancer and targeted therapy. **2007**, 1, 241-58	18
652	Understanding and treating triple-negative breast cancer. **2008**, 22, 1233-9; discussion 1239-40, 1243	167

651	New developments in treatment of ovarian carcinoma: focus on trabectedin. **2010**, 2, 233-42	
650	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. **2011**, 3, 251-8	1
649	AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. **2010**, 1, 691-9	20
648	The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. **2011**, 1, 301-327	23
647	PARP-1 and PARP-2: New players in tumour development. **2011**, 1, 328-346	54
646	Base excision repair targets for cancer therapy. **2011**, 1, 845-51	8
645	Next-generation sequencing for cancer diagnostics: a practical perspective. **2011**, 32, 177-95	246
644	Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. **2010**, 1, 606-19	20
643	BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9. **2012**, 2, 540-8	7
642	Hypoxia and DNA repair. **2013**, 86, 443-51	19
641	BRCA2: one small step for DNA repair, one giant protein purified. **2013**, 86, 479-89	8
640	Approaches to identifying synthetic lethal interactions in cancer. **2015**, 88, 145-55	28
639	Role of PARP-1 in prostate cancer. **2015**, 3, 1-12	13
638	Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis. **2015**, 1, e127	6
637	Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients. **2015**, 8, 7059-71	10
636	PARP1 Inhibitors: antitumor drug design. **2015**, 7, 27-37	27
635	'BRCAness' and its implications for platinum action in gynecologic cancer. **2014**, 34, 551-6	48
634	Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine. **2016**, 8, 108-15	5

633	BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells. **2016**, 2, 31-38	5
632	Olaparib in Epithelial Ovarian Cancer. **2016**, 7, 756-761	
631	[Advances on Recognizing and Managing Tumor Heterogeneity]. **2018**, 21, 712-718	1
630	Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer. **2018**, 9, 36-49	3
629	[New Advances in the Treatment for Small Cell Lung Cancer]. **2019**, 22, 355-362	0
628	Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells. **2019**, 23, 312-23	3
627	Cell Death Response to DNA Damage. **2019**, 92, 771-779	21
626	Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells. **2019**, 12, 3915-3920	7
625	[Highlights of PAPR Inhibitors in Small Cell Lung Cancer]. **2020**, 23, 806-810	
624	The role of Aurora-A in human cancers and future therapeutics. **2020**, 10, 2705-2729	9
623	The Role of the MCTS1 and DENR Proteins in Regulating the Mechanisms Associated with Malignant Cell Transformation. **2021**, 13, 98-105	
622	Loss of MED12 activates the TGF pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells. **2021**,	2
621	Variants of Uncertain Significances in Hereditary Breast and Ovarian Cancer. **2021**, 47-64	
620	Genetic and genomic medicine relevance to cancer prevention, diagnosis, and treatment. **2022**, 237-269	
619	Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. **2022**, 32, 3-14	1
618	Genomic instability, inflammatory signaling and response to cancer immunotherapy. **2021**, 1877, 188661	8
617	PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. **2021**, 15, 101283	2
616	The Role of the MCTS1 and DENR Proteins in Regulating the Mechanisms Associated with Malignant Cell Transformation. **2021**, 13, 98-105	0

615	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.. **2021**, 11, 769280	3
614	Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours. **2021**, 13,	1
613	RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.	0
612	The Abscission Checkpoint: A Guardian of Chromosomal Stability.. **2021**, 10,	2
611	POGZ promotes homology-directed DNA repair in an HP1-dependent manner. **2021**, e51041	0
610	DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma. **2021**, 17, e1009562	2
609	Cancer Patient Healthcare Analysis by Genomic Prediction. **2022**, 387-410	
608	RNA m6A methylation regulators in ovarian cancer. **2021**, 21, 609	6
607	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. **2021**, 81, 4692-4708.e9	8
606	PARP Inhibitors - Trapped in a Toxic Love Affair. **2021**, 81, 5605-5607	3
605	Mammalian Chemical Genomics towards Identifying Targets and Elucidating Modes-of-Action of Bioactive Compounds. **2021**,	0
604	Pathogenic Variants as Biomarkers for Risk in Prostate Cancer. **2021**, 13,	1
603	Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. **2021**,	56
602	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. **2021**, 2, 514-530	3
601	RIF1-ASF1-mediated high-order chromatin structure safeguards genome integrity.	
600	The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.. **2021**, 2, 1357-1371	4
599	Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair. **2021**, 22,	4
598	Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes. **2021**, 12, 1075	1

597	Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. **2021**,	4
596	WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells. **2021**, 12, 6561	1
595	Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation. **2021**, 14, 5353-5360	0
594	LncRNA NFYC-AS1 promotes the development of lung adenocarcinomas through autophagy, apoptosis, and MET/c-Myc oncogenic proteins.. **2021**, 9, 1621	0
593	MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. **2021**, 25, 11157-11169	2
592	Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.. **2021**,	0
591	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. **2021**, 13,	2
590	Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery. **2021**, 22,	3
589	Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. **2021**, 89, 141	0
588	Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. **2021**, 14, 5363-5372	0
587	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. **2021**, 159, 283-295	1
586	Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. **2021**,	0
585	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. **2021**, 12, 7064	3
584	Pleiotropic role of PARP1: an overview.. **2022**, 12, 3	0
583	Meeting report of the 4th biennial Metabolism and Cancer symposium. **2021**,	
582	Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy. **2021**, 68, 213-219	2
581	BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair. **2021**,	2
580	History, Advancements, and Future Strategies. **2021**, 1-14	

579	Chemoprevention for Breast Cancer. **2021**, 129-148	
578	Molecular Basis of BRCA1 and BRCA2: Homologous Recombination Deficiency and Tissue-Specific Carcinogenesis. **2021**, 15-29	
577	in silico-Based Virtual Screening and Molecular Docking Analysis of Phytochemicals obtained from Methanolic Extract of Cleome viscosa Linn. by GC-MS Method for its Anticancer Activity. **2021**, 33, 2943-2952	
576	PARP Inhibitors: Mechanism of Action. **2021**, 281-292	
575	ScalpelSig Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures.. **2022**,	
574	Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells.. **2022**, 1-13	0
573	Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities.. **2021**, 230, 114094	1
572	Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia. **2021**, 26, 904-913	1
571	PARP Inhibitors in Pancreatic Cancer.. **2021**, 27, 465-475	1
570	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.. **2021**, 27, 441-456	1
569	Nuclear NAD+ homeostasis is essential for naive and chemoresistant BRCA1/2-deficient tumor survival.	
568	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.. **2022**, 119,	5
567	Prostate cancer immunotherapy.. **2022**, 1-14	2
566	Transcriptomics reveals efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models.. **2022**, 13, 1-12	
565	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.. **2022**, 14,	0
564	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.. **2022**, 22, 13	1
563	THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.. **2022**, 23,	0
562	Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer.. **2022**,	0

561	Hormonal and Targeted Treatments in Breast Cancer. **2022**, 443-463	2
560	Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.. **2022**, 1-14	
559	Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling.	0
558	An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.. **2022**, 29, 544-550	1
557	Identification and Characterization of an Exonic Duplication in in a Man with Synchronous Breast and Prostate Cancer.. **2022**, 23,	
556	Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.. **2022**, 19, 233-241	
555	Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.. **2021**, 9, 801200	5
554	Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.. **2021**, 1-27	
553	BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.. **2022**,	2
552	Tumour Markers, Prognostic and Predictive Factors in Breast Cancer. **2022**, 221-241	1
551	Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.. **2022**, 15, 10	2
550	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.. **2022**,	2
549	XRCC1 Prevents Replication Fork Instability during Misincorporation of the DNA Demethylation Bases 5-Hydroxymethyl-2'-Deoxycytidine and 5-Hydroxymethyl-2'-Deoxyuridine.. **2022**, 23,	
548	53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Pol□primase fill-in synthesis.. **2022**, 24, 51-61	4
547	Neurofibromin and suppression of tumorigenesis: beyond the GAP.. **2022**,	0
546	PARP mediated DNA damage response, genomic stability and immune responses.. **2021**,	3
545	Glioblastoma Cells Counteract PARP Inhibition through Pro-Survival Induction of Lipid Droplets Synthesis and Utilization.. **2022**, 14,	
544	Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of and Homologous Recombination Genes.. **2022**, 10,	0

543	CRL4-DCAF8L1 Regulates BRCA1 and BARD1 Protein Stability.. **2022**, 18, 1434-1450	1
542	Systemic therapy for triple-negative breast cancer: A changing landscape.. **2022**, 171, 103608	
541	Veliparib for the treatment of solid malignancies.. **2022**, 10781552221073990	1
540	A case□control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique. **2022**, 23,	0
539	Miscoding and DNA Polymerase Stalling by Methoxyamine-Adducted Abasic Sites.. **2022**,	0
538	Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.. **2022**, 14,	1
537	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.. **2021**,	1
536	Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.. **2022**, 230, 114109	7
535	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.. **2021**,	1
534	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. **2022**, 13, 96	1
533	Therapeutic Targeting of DNA Damage Response in Cancer.. **2022**, 23,	1
532	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.. **2022**, 104, 102337	0
531	C. elegans as a model organism to study female reproductive health.. **2022**, 266, 111152	1
530	The emerging role of long noncoding RNA RMRP in cancer development and targeted therapy.. **2022**,	
529	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?. **2022**, 14,	1
528	High-content CRISPR screening. **2022**, 2,	10
527	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.. **2022**,	5
526	BRCA associated prostate cancer. BRCA heredity of one family. **2022**, 17, 157-164	

525	PARP-remmers bij gemetastaseerde prostaatkanker: een systematische review.	
524	NAD in COVID-19 and viral infections.. **2022**,	7
523	Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.. **2022**, 13,	4
522	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.. **2022**, 104, 102359	0
521	Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib.. **2022**, 7, 6313-6321	
520	The role of PARP inhibitors in gastrointestinal cancers.. **2022**, 103621	0
519	PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.. **2021**, 11, 724104	1
518	Guiding ATR and PARP inhibitor combinations with chemogenomic screens.	
517	Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting.. **2021**, e2102853	1
516	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. **2021**, 168, 103539	4
515	Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis.. **2021**,	2
514	p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade.. **2021**,	0
513	Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management.. **2021**, 13,	0
512	Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for -mutated breast cancer: A systematic review and meta-analysis.. **2021**, 17, 1672-1678	
511	Targeting the Replication Stress of Glioblastoma. **2022**, 12, 42-51	
510	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.. **2022**, 14,	1
509	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. **2021**,	2
508	Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1.. **2022**, 12, 828684	4

507	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.. **2022**, 14,	3
506	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. **2022**, 2, CD007929	4
505	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. **2022**, 6, e2100159	0
504	Gynecologic Oncology: On the Shoulders of Giants. **2022**, 43, 034-039	
503	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.. **2022**, 14, 673-686	0
502	Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer.. **2022**, 37, 53-61	
501	DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.. **2022**, 14,	1
500	Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.. **2022**, 14,	0
499	RIF1-ASF1-mediated high-order chromatin structure safeguards genome integrity.. **2022**, 13, 957	0
498	Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer.. **2022**, 14, e22575	0
497	VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.. **2022**, 23,	2
496	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer. **2022**, 20, 1-11	
495	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.. **2022**, 14,	1
494	Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.. **2022**,	1
493	Inhibitors of PARP: Number crunching and structure gazing.. **2022**, 119, e2121979119	3
492	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.. **2022**, 23,	1
491	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.. **2022**, 23,	2
490	DNA-Protein Crosslinks and Their Resolution.. **2022**,	2

489	Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers.. **2022**,	0
488	Computational methods, databases and tools for synthetic lethality prediction.. **2022**,	1
487	Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.. **2022**, 8, 43	
486	Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging.	
485	S6K1 phosphorylates Cdk1 and MSH6 to regulate DNA repair.	
484	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening.. **2022**, 12, 755053	2
483	A review on recent PARP inhibitor advancements in cancer therapy.. **2022**, 18,	
482	DNA damage response inhibition-based combination therapies in cancer treatment: Recent advances and future directions. **2022**, 3, 44-67	0
481	A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.. **2022**, 23,	0
480	HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.. **2022**, 13, 263	1
479	Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.. **2022**, 5, 251	0
478	Translational advances in pancreatic ductal adenocarcinoma therapy.. **2022**, 3, 272-286	12
477	DNA repair defects in cancer and therapeutic opportunities.. **2022**, 36, 278-293	2
476	The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.. **2022**,	4
475	PARP inhibition impedes the maturation of nascent DNA strands during DNA replication.. **2022**,	1
474	PARP Inhibitor Decreases Akt Phosphorylation and Induces Centrosome Amplification and Chromosomal Aneuploidy in CHO-K1 Cells.. **2022**, 23,	
473	Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.. **2022**,	0
472	The role of genetic testing in prostate cancer screening, diagnosis, and treatment.. **2022**,	

471	Recent Progress of the research on the benzimidazole PARP-1 inhibitors.. **2022**,	
470	Profiling of the ADP-Ribosylome in Living Cells.	0
469	Profiling of the ADP-Ribosylome in Living Cells.. **2022**,	2
468	PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. **2022**,	
467	PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.. **2022**,	1
466	Combination Therapy Case Studies in Anticancer and Anti-Infectious Disease Drug Discovery and Development. **2022**, 341-384	
465	Role of Paralogue of XRCC4 and XLF in DNA Damage Repair and Cancer Development.. **2022**, 13, 852453	1
464	XRCC1 counteracts PARP poisons, Olaparib and Talazoparib, and a clinical alkylating agent, Temozolomide, by promoting the removal of trapped PARP1 from broken DNA.. **2022**,	1
463	BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.. **2022**, 10, 813457	1
462	-Carbamoyl Alanine-Mediated Selective Targeting for CHEK2-Null Colorectal Cancer.. **2022**, 7, 13095-13101	1
461	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.. **2022**, 14,	0
460	Bladder cancer organoids as a functional system to model different disease stages and therapy response.	
459	The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects.. **2022**, 2022, 2800488	
458	Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.. **2022**, 116739	1
457	Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation.. **2022**,	3
456	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. **2022**, JCO2102767	7
455	The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays.. **2022**,	1
454	A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).. **2022**,	0

453	Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial.. **2022**,		0
452	BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.. **2022**, 12, 766794		
451	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Proficient and Deficient Murine Ovarian Cells.. **2022**, 14,		1
450	Dual-target inhibitors based on PARP1: new trend in the development of anticancer research.. **2022**,		
449	Expression of BRCA1, BRCA2, RAD51, and other DSB repair factors is regulated by CRL4.. **2022**, 113, 103320		0
448	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.. **2022**, 166, 87-99		2
447	Evaluation of Poly(ADP-ribose) Polymerase Inhibitor, Pamiparib (BGB-290) in Treating Acute Myeloid Leukemia and the Characterization of Its Nanocarrier.. **2021**, 17, 2165-2175		
446	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.. **2021**, 27, 482-490		
445	Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.. **2021**, 27, 521-528		1
444	PARP Inhibition in Advanced Prostate Cancer.. **2021**, 27, 457-464		0
443	What's next for PARP inhibitors?. *Nature*, **2021**, 600, S36-S38	50.4	0
442	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.. **2021**, 13,		6
441	Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.. **2021**, 11, 772604		0
440	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.. **2021**, 14,		1
439	Biosensors for Point Mutation Detection.. **2021**, 9, 797831		0
438	Targeting DNA repair pathway in cancer: Mechanisms and clinical application.. **2021**, 2, 654-691		3
437	Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.. **2021**, 12, 777663		1
436	Tools for Decoding Ubiquitin Signaling in DNA Repair.. **2021**, 9, 760226		0

435	PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?. **2021**, 15, ed118	0
434	Targeting BRCA-mutated tumors in mitosis.. **2021**, 2, 1296-1297	
433	Insilico and Invitro optimization of Naringin and rutin molecules targeting DNA damage in breast cancer cells.	
432	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.. **2021**, 14,	0
431	PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.. **2021**, 12, 762989	2
430	and Metastasis: Outcome of Defective DNA Repair.. **2021**, 14,	0
429	A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. **2021**, 13, 186	2
428	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.. **2021**, 12, 3133-3140	0
427	Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.. **2022**, 3, 156-172	2
426	The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells.. **2022**, 14,	0
425	Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.. **2022**, 11,	1
424	Oncology Drug Repurposing for Sepsis Treatment.. **2022**, 10,	
423	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. **2022**, 89, 721	0
422	CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.	
421	Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.. **2022**,	1
420	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.. **2022**, 89, 683	1
419	Precision combination therapies based on recurrent oncogenic co-alterations.. **2022**,	1
418	BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination.. **2022**, 115, 103331	

417	Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells.. **2022**, 41, 140	0
416	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy.. **2022**, 2022, 4880355	1
415	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.. **2022**, JCO2101511	3
414	Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation.. **2022**, 113163	3
413	Engineered cellular immunotherapies in cancer and beyond.. **2022**, 28, 678-689	6
412	Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.. **2022**, 79, 104001	2
411	Image_1.TIF. **2020**,	
410	Table_1.xlsx. **2020**,	
409	Data_Sheet_1.pdf. **2019**,	
408	Table_1.docx. **2020**,	
407	Table_2.docx. **2020**,	
406	Table_3.docx. **2020**,	
405	DataSheet_1.pdf. **2020**,	
404	Image_1.pdf. **2019**,	
403	Data_Sheet_1.docx. **2020**,	
402	Image_1.TIF. **2019**,	
401	Table_1.XLSX. **2019**,	
400	presentation1.pdf. **2020**,	

399	Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS.. **2022**,	1
398	Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.. **2022**,	0
397	loss overrides PARP inhibitor sensitivity driven by loss in prostate cancer.. **2022**, 8, eabl9794	0
396	Tumor-intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality.. **2022**,	3
395	Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.. **2022**, 16, 11782234221080553	
394	Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. **2021**, 25,	2
393	Clinical Evidence in Gynaeoncology: Sources and Application. **2022**, 35-49	
392	Novel biomarkers in triple-negative breast cancer - role and perspective. **2022**, 29-60	
391	Dynamics of Endogenous PARP1 and PARP2 During DNA Damage Revealed by Live-Cell Single-Molecule Imaging.	
390	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.. **2022**, 11,	0
389	Biomolecular condensates govern PARP inhibitor trapping and present mechanisms of resistance.	
388	Rationale and design of the phase 3 KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage III non-small-cell lung cancer. **2022**,	1
387	Exploiting replication gaps for cancer therapy.. **2022**,	3
386	Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.. **2022**,	
385	Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.. **2022**, 8, eabm6638	1
384	Combinatorial Treatment with Poly(ADP-ribose) Polymerase-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth Through Fos-Driven Changes in Gene Expression.. **2022**,	0
383	Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment.. **2022**,	0
382	METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/Rad51 axis.. **2022**, 11,	0

381	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared to Other PARP Inhibitors.. **2022**,	0
380	The lactate-NAD axis activates cancer-associated fibroblasts by downregulating p62.. **2022**, 39, 110792	2
379	Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime. **2022**,	0
378	OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. **2022**, 12,	0
377	Radiogenomics: A Valuable Tool for the Clinical Assessment and Research of Ovarian Cancer.. **2022**, 46, 371-378	
376	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.. **2022**, 8, 64	
375	Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.. **2022**, 215716	2
374	Charted Territory: Evidence from Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical Industry.	
373	Resistance to DNA repair inhibitors in cancer.. **2022**,	2
372	Ovarian, Vaginal, and Vulvar Cancer. **2022**, 317-339	
371	RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair via Homologous Recombination. **2022**, 10,	0
370	Targeting the DNA damage response and repair in cancer through nucleotide metabolism.. **2022**,	1
369	First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.. **2022**,	1
368	Methods for profiling the target and off-target landscape of PARP inhibitors. **2022**, 2, 100027	
367	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. **2022**,	2
366	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. **2022**, 14, 2504	1
365	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. **2022**, 23, 5770	0
364	Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. **2022**, 13,	

363	Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. **2022**, 14, 2640	2
362	Systemic Therapies for Pancreatic Cancer. **2022**, 193-200	
361	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. **2022**, 1-13	0
360	Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.	3
359	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. **2022**, 13,	1
358	The Role of DNA Repair in Genomic Instability of Multiple Myeloma. **2022**, 23, 5688	0
357	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. **2022**, 14, 2588	0
356	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. **2022**,	1
355	Synthetic lethality between TP53 and ENDOD1. **2022**, 13,	0
354	Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. **2022**,	
353	Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. **2022**, 10,	
352	Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress. **2022**, 12,	1
351	Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors. **2022**, 14, 2804	1
350	Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. **2022**, 61,	0
349	A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.	0
348	PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. **2022**, 11,	2
347	RecQ Helicase Somatic Alterations in Cancer. 9,	0
346	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. 9,	

345	Exploring the genetic space of the DNA damage response for cancer therapy through CRISPR-based screens.	0
344	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. **2022**, 10, 1416	3
343	Telomere Maintenance and the cGAS-STING Pathway in Cancer. **2022**, 11, 1958	
342	Circulating tumor DNA: current challenges for clinical utility. **2022**, 132,	1
341	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. **2022**, 7,	4
340	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. **2022**, 14, 2950	0
339	Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. 12,	1
338	Germline Mutations in Patients With Early-Onset Prostate Cancer. 12,	1
337	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.	0
336	Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis.	1
335	The immune landscape of solid pediatric tumors. **2022**, 41,	1
334	Inhibitors of ROCK kinases induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.	
333	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. **2022**,	
332	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. **2022**, 14, 3239	2
331	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. **2022**, 14, 3175	0
330	WRN rescues replication forks compromised by a BRCA2 deficiency: Predictions for how inhibition of a helicase that suppresses premature aging tilts the balance to fork demise and chromosomal instability in cancer. 2200057	0
329	A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Volume 14, 789-802	0
328	PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. **2022**, 6,	0

327	Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. **2022**, 19, 8113	4
326	Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery. **2022**,	1
325	Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. 12,	
324	Synthesis and Evaluation of a New Series of Spiro Aryl Dioxolane Compounds: A New Scaffold as Potential PARP -1 Inhibitors.	
323	Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer. 13,	1
322	DNA repair as a shared hallmark in cancer and ageing.	1
321	Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.	2
320	Tutorial: design and execution of CRISPR in vivo screens.	1
319	Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.	1
318	Tracing back primed resistance in cancer via sister cells.	
317	Comparison of Adverse Reactions Caused by Olaparib for Different Indications. 13,	
316	Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. **2022**, 40, 111081	1
315	A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. 13,	
314	Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas.	
313	Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation. **2022**, 42, 101044	1
312	Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?. **2022**, 7, 100536	1
311	Synthesis and biological evaluation of a tumor-selective degrader of PARP1. **2022**, 69, 116908	0
310	Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone. **2022**, 240, 114574	1

309	Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib. **2022**, 2022, 1-11	0
308	Opinion: PARP inhibitors in cancer□what do we still need to know?. **2022**, 12,	0
307	PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. **2022**, 12,	
306	The APE2 nuclease is essential for DNA double strand break repair by microhomology-mediated end-joining.	1
305	Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity. **2022**, 13,	
304	Mechanistic basis for targeting homologous recombination defective liver cancer via synthetic lethality.	
303	Platinum anticancer drugs: Targeting and delivery. **2022**,	
302	Emerging Role of Structural and Systems Biology in Anticancer Therapeutics. **2022**, 97-114	
301	Identify non-mutational p53 loss of function in human cancers.	
300	DNA Damage Response Regulation by Histone Ubiquitination. **2022**, 23, 8187	0
299	Mechanism-based design of agents that selectively target drug-resistant glioma. **2022**, 377, 502-511	0
298	Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. **2022**, 22,	
297	Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.	0
296	Live Cell Detection of Poly(ADP-Ribose) for Use in Genetic and Genotoxic Compound Screens. **2022**, 14, 3676	1
295	Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report. **2022**, 17,	1
294	ATM and MSH2 control blunt DNA end joining in immunoglobulin class switch recombination.	
293	Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. **2022**,	0
292	Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. **2022**, 14, 3528	2

291	Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. **2022**, 13,	0
290	Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy. **2022**, 27, 4736	1
289	Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.	1
288	Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition.	0
287	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. **2022**, 23, 8412	3
286	Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.	1
285	Functional roles of ADP-ribosylation writers, readers and erasers. 10,	
284	Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection. **2022**, 13,	3
283	Counting the cost of public and philanthropic R&D funding: the case of olaparib. **2022**, 15,	
282	Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.	0
281	Synthetic lethality in personalized cancer therapy.	
280	Analytical Principles of Cancer Next Generation Sequencing. **2022**,	2
279	RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors. **2022**, 102354	
278	Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. 13,	0
277	MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.	
276	Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. **2022**, 2022, 1-27	
275	Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets. **2022**, 23, 8875	2
274	Triple negative breast cancer: approved treatment options and their mechanisms of action.	1

273	Tieing together loose ends: telomere instability in cancer and aging.	0
272	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. **2022**, 14, 3888	5
271	DNA Repair Inhibitors Potentiate Fractionated Radiotherapy More Than Single-Dose Radiotherapy in Breast Cancer Cells. **2022**, 14, 3794	
270	MDC1 counteracts restrained replication fork restart and its loss causes chemoresistance in BRCA1/2-deficient mammary tumors.	
269	The disruption of the CCDC6 PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma. **2022**, 41,	
268	Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma. 12,	2
267	Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. **2022**,	0
266	Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma.	
265	Capturing a Pentacyclic Fragment-Based Library Derived from Perophoramidine: Their Design, Synthesis and Evaluation as Anticancer Compounds via DNA Double-Strand Breaks (DSB) and PARP-1 Inhibition.	
264	Therapy resistance mechanisms in hematological malignancies.	1
263	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. 12,	3
262	Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.	0
261	Targeted therapy for breast cancer: An overview of drug classes and outcomes. **2022**, 204, 115209	2
260	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. **2022**, 52, 101595	1
259	The fast-growing business of Serine ADP-ribosylation. **2022**, 118, 103382	0
258	Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?. **2022**, 110, 102459	0
257	BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. **2022**, 40, 111304	0
256	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. **2022**, 7, 100558	0

255	Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors. **2022**, 184, 106425	0
254	Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway. **2022**, 420, 113338	1
253	The Base Excision Repair (BER) Pathway. **2022**,	0
252	The In-Cell Western immunofluorescence assay to monitor PROTAC mediated protein degradation. **2022**,	0
251	Research Progress of PARP1 in Hepatocellular Carcinoma. **2022**, 12, 6893-6899	0
250	Oncometabolites, epigenetic marks, and DNA repair. **2022**, 191-202	0
249	CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair. **2022**, 40, 111297	1
248	Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. 12,	0
247	USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells.	0
246	[1,2,4]Triazolo[3,4-b]benzothiazole scaffold as versatile nicotinamide mimic allowing nanomolar inhibition of different PARP enzymes.	0
245	Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition.	0
244	A high-resolution, nanopore-based artificial intelligence assay for DNA replication stress in human cancer cells.	0
243	GRETA: an R package for mapping in silico genetic interaction and essentiality networks.	1
242	Cisplatin Resistance: Genetic and Epigenetic Factors Involved. **2022**, 12, 1365	0
241	Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer. **2022**, 24,	0
240	PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma. **2022**,	1
239	BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making. **2022**, 14, 4571	0
238	A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer. **2022**, 21, 156-164	0

237	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.	0
236	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. 13,	0
235	Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. **2022**, 29,	2
234	Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. **2022**, 13,	0
233	A two-step mechanism governing PARP1-DNA retention by PARP inhibitors. **2022**, 8,	2
232	Effect of the PARP inhibitor veliparib on germ cell tumor cell lines. **2022**, 24,	0
231	Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers.	0
230	The DNA damage checkpoint: A tale from budding yeast. 13,	0
229	ATF6-mediated signaling contributes to PARP Inhibitor Resistance in Ovarian Cancer.	0
228	Niraparib (Zejula), A Small Molecule, PARP1/2 Inhibitor for Treating Breast, Ovarian, and Pancreatic Cancers. **2022**, 231-251	0
227	Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of Second Hit in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.	0
226	Recent advances in cancer therapy using PARP inhibitors. **2022**, 39,	0
225	Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer. **2022**, 102550	0
224	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. **2022**, 14, 4332	2
223	Potent and selective PTDSS1 inhibitors induce collateral lethality in cancers with PTDSS2 deletion.	0
222	Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. **2022**, 14, 4621	0
221	Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.	0
220	Radioresistance in rhabdomyosarcomas: Much more than a question of dose. 12,	0

219	METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. **2022**, 3, 1088-1104	2
218	Targeting the DNA damage response in pediatric malignancies. 1-15	0
217	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. Volume 15, 1105-1117	1
216	CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer. **2022**, 215944	0
215	Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.	0
214	THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. **2022**, 103409	0
213	Plasma, cancer, immunity. **2022**, 55, 473003	2
212	S6K1 phosphorylates Cdk1 and MSH6 to regulate DNA repair. 11,	0
211	Epistasis and evolutionary dependencies in human cancers. **2022**, 77, 101989	0
210	Targeted Molecular Therapy for Ovarian Cancer Patients. **2022**, 179-203	0
209	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. **2022**, 59-76	0
208	BRCA1?DNA????????. **2022**,	0
207	Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.	1
206	PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination. **2022**, 23, 12876	0
205	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. **2022**, 23, 1566-1589	1
204	Cancer Genomics and Evolution. 1-30	0
203	TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. **2022**, 14, 5240	0
202	Nimbolide Targets RNF114 to Induce the Trapping of PARP1 and Poly-ADP-Ribosylation-Dependent DNA Repair Factors.	0

201	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. **2022**, 15,	1
200	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. **2022**, 29,	0
199	Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. **2022**, 23, 12647	0
198	Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects. **2022**, 42, 1009-1016	0
197	Hereditary ovarian cancer. **2022**, 21, 123-134	0
196	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. **2022**, 13,	0
195	Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality. **2022**, 221,	0
194	Revealing the functions of clonal driver gene mutations in patients based on evolutionary dependencies.	0
193	A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors. 13,	1
192	PBRM1, SETD2 and BAP1 □the trinity of 3p in clear cell renal cell carcinoma.	0
191	Targeting the ALK□CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. **2022**, 3, 1211-1227	0
190	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 1-23	0
189	Expanding biomarkers for PARP inhibitors. **2022**, 3, 1141-1143	0
188	Construction and analysis of sample-specific driver modules for breast cancer. **2022**, 23,	0
187	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. **2022**,	1
186	BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. **2022**, 13,	1
185	Ubiquitinated PCNA drives USP1 synthetic lethality in cancer.	0
184	Principles of Radiation Oncology. 1-10	0

183	Pyridazinones: A versatile scaffold in the development of potential target-based novel anticancer agents.	0
182	Leveraging the replication stress response to optimize cancer therapy.	2
181	Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. **2022**, 23, 13356	1
180	Exploring the DNA damage response pathway for synthetic lethality.	0
179	Emerging concepts in drug discovery for cancer therapy. **2022**, 16, 3757-3760	0
178	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. 1-12	0
177	Transgenic mice harboring direct repeat substrates reveal key underlying causes of homologous recombination in vivo. **2022**, 120, 103419	0
176	A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein. **2022**, 120, 103421	1
175	A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. **2022**, 206, 115329	0
174	Self-delivery photodynamic sensitizer for enhanced DNA damage by PARP inhibition.	0
173	Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors. **2022**, 4,	0
172	Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.	0
171	Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51. **2022**, 13,	2
170	PARP Inhibitor for Ovarian Cancer Therapy. **2022**, 4, 1-7	0
169	Clinical prospects of WRN inhibition as a treatment for MSI tumours. **2022**, 6,	1
168	SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma. **2022**, 8,	0
167	Regulation of BRCA1 stability through the tandem UBX domains of isoleucyl-tRNA synthetase 1. **2022**, 13,	0
166	BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. **2022**, 14, 5619	0

165	A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. 13,	0
164	Current Status and Prospects of Targeted Therapy for Osteosarcoma. **2022**, 11, 3507	1
163	Development of a novel BRCAness score that predicts response to PARP inhibitors. **2022**, 10,	0
162	Obesity Influences the Expression of Key Immunomodulators in Normal Human Breast Tissue, Basal-like Breast Cancer Patients, and Cell Lines. **2022**, 14, 5599	0
161	A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma.	0
160	Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer.	0
159	Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling. **2022**, 14, 5559	0
158	Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.	0
157	Brca1 and Tp53 co-deficiency causes a PARP-inhibitor sensitive erythroproliferative neoplasm.	0
156	PARP1 proximity proteomics reveals interaction partners at stressed replication forks.	0
155	Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers. **2022**, 78, 129046	0
154	Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. **2022**, 14, 5633	0
153	DNA Repair by Homologous Recombination. **2016**, 567-579	0
152	Drug Addiction in Cancer. **2022**, 1-17	0
151	Epigenetic basis for PARP mutagenesis in glioblastoma: A review. **2023**, 938, 175424	0
150	Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging. **2023**, 26, 105779	2
149	Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy. **2023**, 1878, 188842	0
148	Systemic Therapy for Hereditary Breast Cancers. **2023**, 37, 203-224	0

147	Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. **2022**, 4,	1
146	Clonal Hematopoiesis and Its Impact on Human Health. **2023**, 74,	0
145	Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome. **2022**, 2022,	0
144	The Role of 8-oxoG Repair Systems in Tumorigenesis and Cancer Therapy. **2022**, 11, 3798	0
143	Harnessing immunomodulation during DNA damage in Ewing sarcoma. 12,	0
142	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. **2022**, 23, 14672	0
141	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. **2022**, 14, 5795	0
140	3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction. 12,	0
139	Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. **2022**, 13,	0
138	Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. **2022**, 14, 5922	0
137	Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.	0
136	Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling. **2022**, 14,	0
135	Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers. **2022**, 14, 5953	1
134	Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.	0
133	53BP1: Keeping It under Control, Even at a Distance from DNA Damage. **2022**, 13, 2390	0
132	Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors. **2022**, 29, 1694-1708.e10	1
131	Targeting homologous recombination repair in BCR/ABL1-positive cells using PARP inhibitor.	0
130	Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research1-20	0

129	Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İnhibisyonu Arasındaki Sentetik Letal Etkileşim. 2459-2475	0
128	Hereditary breast cancer: syndromes, tumour pathology and molecular testing. **2023**, 82, 70-82	4
127	Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment. 13,	0
126	The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. **2022**, 54, 1853-1864	1
125	Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. Volume 15, 1509-1518	0
124	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. **2023**, 15, 104	0
123	Rational combinations of targeted cancer therapies: background, advances and challenges.	1
122	Analyzing PARP1 Activity: Small Molecule Reactants and Attached Chains of Poly (ADP-Ribose). **2023**, 61-73	0
121	Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment. **2022**, 65, 16099-16127	0
120	Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images. **2022**, 3, 100872	2
119	Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?.	0
118	PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells. **2022**, 23, 16171	0
117	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. 9,	0
116	PSIP1/LEDGF reduces R-loops at transcription sites to maintain genome integrity.	0
115	Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: a drug–drug interaction study.	0
114	Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector. 12,	0
113	Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast cancers.	0
112	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. **2022**,	0

111	Targeting DNA damage response pathways in cancer.	9
110	The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. **2022**, 41, 111819	1
109	Evolving DNA repair synthetic lethality targets in cancer. **2022**, 42,	1
108	Epigenetic Insights on PARP-1 Activity in Cancer Therapy. **2023**, 15, 6	0
107	Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology. 12,	0
106	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. **2023**, 16,	0
105	Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.	0
104	RNAi screening reveals a synthetic chemical-genetic interaction between ATP synthase and PFK1 in cancer cells.	1
103	STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. **2023**, 11, e005627	0
102	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. **2023**, 15, 448	0
101	CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. **2023**, 14,	1
100	Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma. **2023**, 6,	0
99	Targeting the DNA damage response for cancer therapy.	0
98	Ataxia Telangiectasia Mutated and MSH2 Control Blunt DNA End Joining in Ig Class Switch Recombination.	0
97	Interleukin-34 cancels anti-tumor immunity by PARP inhibitor. 34,	0
96	Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors.	0
95	[1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes.	0
94	Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts.	0

93	Cancer Cell Resistance to IFNΓ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity.	0
92	Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments. **2023**, 15, 368	0
91	BLM helicase determines chemotherapy-induced responses of human glioma cells and shifts between apoptosis, senescence or polyploidy.	0
90	Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. **2023**, 114, 102511	0
89	PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma. **2023**, 15, 203636132311523	0
88	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. ijgc-2022-003990	0
87	Characterizing inhibitors of human AP endonuclease 1. **2023**, 18, e0280526	0
86	Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. **2023**, 5,	1
85	Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition. **2023**, 24, 2040	1
84	Replication gap suppression depends on the double-strand DNA binding activity of BRCA2. **2023**, 14,	0
83	Cytosolic DNA sensing by cGAS/STING promotes TRPV2-mediated Ca2+ release to protect stressed replication forks. **2023**,	0
82	Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.	0
81	DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation. **2023**, 14,	0
80	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. 13,	0
79	A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.	1
78	Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.	0
77	PARP Inhibitors and Proteins Interacting with SLX4. **2023**, 15, 997	0
76	Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. **2023**, 12, 667	0

75	Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. **2023**, 172, 121-129	0
74	Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1. **2023**, 251, 115243	0
73	The association between TIPARP gene polymorphisms rs2665390 and ovarian cancer susceptibility. **2023**, 47, 101175	0
72	Targeting synthetic lethal paralogs in cancer. **2023**,	0
71	PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage. **2023**, 646, 78-85	0
70	Quantification of venadaparib, a novel PARP inhibitor, in the rat and dog plasma using liquid chromatography/tandem mass spectrometry. **2023**, 14,	0
69	Synthetic lethal approaches to target cancers with loss of PTEN function. **2023**,	0
68	Pyrosequencing Assay for BRCA1 Methylation Analysis. **2023**, 25, 217-226	0
67	BARD1germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.	0
66	ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. **2023**, 2023, 1-12	1
65	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. **2023**, 15, 1093	0
64	Revolutionizing DNA repair research and cancer therapy with CRISPR□as screens.	0
63	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. **2023**, 15,	1
62	Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). **2023**, 12, 1524	1
61	HDGFRP3 interaction with 53BP1 promotes DNA double-strand break repair. **2023**, 51, 2238-2256	0
60	Rucaparib or Physician□ Choice in Metastatic Prostate Cancer. **2023**, 388, 719-732	1
59	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. **2023**, 22, 333-342	0
58	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. **2023**, 24, 4044	0

57	Predicting gene knockout effects from expression data. **2023**, 16,	0
56	Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. **2023**, 15, 1299	0
55	ARID1A in cancer: Friend or foe?. 13,	0
54	PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. 13,	0
53	TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC.	0
52	Human PARP1 substrates and regulators of its catalytic activity: An updated overview. 14,	0
51	EXO1-mediated DNA repair by single-strand annealing is essential for BRCA1-deficient cells.	0
50	Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer. **2023**, 22, 35-42	0
49	Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.	0
48	DNA Damage and Its Role in Cancer Therapeutics. **2023**, 24, 4741	0
47	Hereditary Breast Cancer and Pathogenic Germline Variants. **2023**, 45-59	0
46	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. **2023**, 15, 175883592311576	0
45	First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report. 13,	0
44	The Cellular Response to Complex DNA Damage Induced by Ionising Radiation. **2023**, 24, 4920	0
43	Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. **2023**, 8, 101154	0
42	DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. **2023**, 15, 1619	0
41	Let□ not take DNA breaks for granted. The importance of direct detection of DNA breaks for the successful development of DDR inhibitors. 11,	0
40	Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib. 13,	0

39	Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?. **2023**, 83, 310-320	0
38	BIN1 in cancer: biomarker and therapeutic target.	0
37	Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials. **2023**, 16, 245-256	0
36	Personalized Systemic Therapies in Hereditary Cancer Syndromes. **2023**, 14, 684	0
35	Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.	0
34	Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation. Volume 16, 195-200	0
33	Interferon restores replication fork stability and cell viability in BRCA-defective cells via ISG15.	0
32	Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.	0
31	Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. **2023**,	0
30	Top advances of the year: Precision oncology.	0
29	Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. **2023**, 9,	0
28	Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling.	0
27	Polymerase Inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. **2023**, 14,	0
26	Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.	0
25	RB loss sensitizes cells to replication-associated DNA damage by PARP inhibition.	0
24	Analysis of the PARP1, ADP-Ribosylation and TRIP12 Triad with Markers of Patient Outcome in Human Breast Cancer. **2023**, 100167	0
23	Tob negatively regulates NF-B activation in breast cancer through its association with the TNF receptor complex..	0
22	Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.	0

21	Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment.	0
20	PROTACing oncoproteins: targeted protein degradation for cancer therapy. **2023**, 22,	0
19	Crosstalk between triple negative breast cancer and microenvironment. **2023**, 14, 284-293	0
18	A Screen Reveals Bexarotene, Sorafenib and Certain of its Analogues as Common and Effective Inhibitors of Growth of Bacteria that Grow on LB but not on McConkey Agar.	0
17	BAP1 as a guardian of genome stability: implications in human cancer.	0
16	Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.	0
15	Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).	0
14	Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.	0
13	Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature.	0
12	The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining. **2023**,	0
11	Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.	0
10	BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair.	0
9	A View on Drug Development for Cancer Prevention. OF1-OF26	0
8	Bladder cancer organoids as a functional system to model different disease stages and therapy response. **2023**, 14,	0
7	PARP Inhibitors in Breast and Ovarian Cancer. **2023**, 15, 2357	0
6	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. ijgc-2022-004211	0
5	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database.	0
4	Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.	0

3	PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. **2023**,	0
2	Olaparib and advanced ovarian cancer: Summary of the past and looking into the future. 14,	0
1	Proximity RNA labeling reveals functions of lncRNA in DNA damage response.	0